EP3088897A1 - Method for predicting therapeutic effect of biological preparation on rheumatoid arthritis - Google Patents
Method for predicting therapeutic effect of biological preparation on rheumatoid arthritis Download PDFInfo
- Publication number
- EP3088897A1 EP3088897A1 EP14867880.8A EP14867880A EP3088897A1 EP 3088897 A1 EP3088897 A1 EP 3088897A1 EP 14867880 A EP14867880 A EP 14867880A EP 3088897 A1 EP3088897 A1 EP 3088897A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- therapy
- determining
- tocilizumab
- value
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 126
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 68
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 44
- 210000002966 serum Anatomy 0.000 claims abstract description 119
- 102000005754 Cytokine Receptor gp130 Human genes 0.000 claims abstract description 94
- 108010006197 Cytokine Receptor gp130 Proteins 0.000 claims abstract description 94
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 70
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 70
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 57
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 55
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 47
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 47
- 208000024891 symptom Diseases 0.000 claims abstract description 47
- 108010002586 Interleukin-7 Proteins 0.000 claims abstract description 36
- 108010002335 Interleukin-9 Proteins 0.000 claims abstract description 34
- 102000000585 Interleukin-9 Human genes 0.000 claims abstract description 34
- 108090001007 Interleukin-8 Proteins 0.000 claims abstract description 32
- 102000004890 Interleukin-8 Human genes 0.000 claims abstract description 32
- 102000003816 Interleukin-13 Human genes 0.000 claims abstract description 31
- 108090000176 Interleukin-13 Proteins 0.000 claims abstract description 31
- 108010081589 Becaplermin Proteins 0.000 claims abstract description 30
- -1 IL-1β Proteins 0.000 claims abstract description 30
- 102100023688 Eotaxin Human genes 0.000 claims abstract description 28
- 101710139422 Eotaxin Proteins 0.000 claims abstract description 28
- 102000003812 Interleukin-15 Human genes 0.000 claims abstract description 28
- 108090000172 Interleukin-15 Proteins 0.000 claims abstract description 28
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract description 26
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims abstract description 26
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 25
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 25
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims abstract description 23
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims abstract description 23
- 108010065805 Interleukin-12 Proteins 0.000 claims abstract description 19
- 102000013462 Interleukin-12 Human genes 0.000 claims abstract description 19
- 108010002616 Interleukin-5 Proteins 0.000 claims abstract description 19
- 102000000743 Interleukin-5 Human genes 0.000 claims abstract description 19
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract description 17
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 17
- 102100037850 Interferon gamma Human genes 0.000 claims abstract description 16
- 102000003814 Interleukin-10 Human genes 0.000 claims abstract description 16
- 108090000174 Interleukin-10 Proteins 0.000 claims abstract description 16
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims abstract 8
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims abstract 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract 6
- 108700012434 CCL3 Proteins 0.000 claims abstract 4
- 102000000013 Chemokine CCL3 Human genes 0.000 claims abstract 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 362
- 229960003989 tocilizumab Drugs 0.000 claims description 153
- 108010008165 Etanercept Proteins 0.000 claims description 121
- 229960000403 etanercept Drugs 0.000 claims description 121
- 238000009472 formulation Methods 0.000 claims description 119
- 239000000203 mixture Substances 0.000 claims description 119
- 102000004127 Cytokines Human genes 0.000 claims description 69
- 108090000695 Cytokines Proteins 0.000 claims description 69
- 239000003550 marker Substances 0.000 claims description 65
- 230000009266 disease activity Effects 0.000 claims description 38
- 230000003092 anti-cytokine Effects 0.000 claims description 32
- 230000008685 targeting Effects 0.000 claims description 15
- 239000000032 diagnostic agent Substances 0.000 claims description 9
- 229940039227 diagnostic agent Drugs 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 101150021185 FGF gene Proteins 0.000 abstract description 2
- 102000006579 Chemokine CXCL10 Human genes 0.000 description 68
- 108010008978 Chemokine CXCL10 Proteins 0.000 description 68
- 238000004458 analytical method Methods 0.000 description 61
- 229940100601 interleukin-6 Drugs 0.000 description 61
- 102000005962 receptors Human genes 0.000 description 54
- 108020003175 receptors Proteins 0.000 description 54
- 238000012417 linear regression Methods 0.000 description 48
- 102000019034 Chemokines Human genes 0.000 description 47
- 108010012236 Chemokines Proteins 0.000 description 47
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 42
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 34
- 102000003777 Interleukin-1 beta Human genes 0.000 description 34
- 108090000193 Interleukin-1 beta Proteins 0.000 description 34
- 102100021592 Interleukin-7 Human genes 0.000 description 31
- 229940100994 interleukin-7 Drugs 0.000 description 31
- 229940118526 interleukin-9 Drugs 0.000 description 29
- 229940096397 interleukin-8 Drugs 0.000 description 27
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 27
- 238000007477 logistic regression Methods 0.000 description 22
- 206010051259 Therapy naive Diseases 0.000 description 20
- 230000002596 correlated effect Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 229940100602 interleukin-5 Drugs 0.000 description 16
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 15
- 102100031092 C-C motif chemokine 3 Human genes 0.000 description 15
- 238000000611 regression analysis Methods 0.000 description 14
- 238000000540 analysis of variance Methods 0.000 description 13
- 239000000090 biomarker Substances 0.000 description 12
- 238000010586 diagram Methods 0.000 description 9
- 229960000598 infliximab Drugs 0.000 description 8
- 229960002964 adalimumab Drugs 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 4
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 4
- 206010023232 Joint swelling Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
- 108010055166 Chemokine CCL5 Proteins 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 3
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 206010071602 Genetic polymorphism Diseases 0.000 description 2
- 101150105318 IRF5 gene Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 2
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 1
- 101100232344 Homo sapiens IL10RB gene Proteins 0.000 description 1
- 101150103958 IL10RB gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present invention relates to a method of predicting and determining a therapeutic effect of a biological formulation on a rheumatoid arthritis patient. More specifically, the present invention relates to a method of predicting and determining a therapeutic effect, such as the level of improvement in a symptom or the possibility of remission, prior to the administration of a biological formulation to a rheumatoid arthritis patient. Furthermore, the present invention relates to a diagnostic agent for predicting and determining a therapeutic effect due to a biological formulation on a rheumatoid arthritis patient.
- Rheumatoid arthritis is a systemic inflammatory disease, which is predominantly a lesion in the articular synovial membrane. It is estimated that approximately 700,000 people suffer from rheumatoid arthritis in Japan. Many biological formulations that target inflammatory cytokines have been developed for rheumatoid arthritis therapy. In recent years, anti-TNF- ⁇ agents or anti-IL-6 agents, which inhibit TNF- ⁇ or IL-6 action, have been used in clinical practices.
- Tocilizumab is a humanized IL-6 receptor antibody, which is an agent that causes rheumatoid arthritis to subside by the action of binding to a membrane-binding IL-6 receptor and a soluble IL-6 receptor to suppress IL-6 signaling.
- etanercept is a fully human soluble TNF/LT ⁇ receptor formulation consisting of a subunit dimer of an extracellular domain of a human tumor necrosis factor II receptor and an Fc region of a human IgG1.
- Etanercept is an agent that binds to both TNF ⁇ / ⁇ to inhibit signaling to a TNF receptor to cause rheumatoid arthritis to subside.
- Adalimumab and infliximab are human and chimeric TNF- ⁇ antibodies, which are agents that cause rheumatoid arthritis to subside by specifically binding to excessively produced TNF- ⁇ and inhibiting the binding of TNF- ⁇ to a TNF- ⁇ receptor.
- Markers for predicting the effectiveness of a biological formulation targeting an inflammatory cytokine on a rheumatoid arthritis patient have been intensively investigated.
- a method of using a microDNA chip, a method of using a CRP value at baseline as an indicator, a method of using blood soluble ICAMI concentration and CXCL13 concentration as indicators, a method of using leukocyte ADAMT5 gene expression amount as an indicator Non Patent Literature 4
- a method of comprehensively analyzing genetic polymorphisms Patent Literatures 1 and 2
- a method of analyzing a genetic mutation of an IL-6 receptor Patent Literature 3
- Patent Literature 4 a method of analyzing the IL10RB gene, the IRF5 gene, and polymorphisms of the IRF5 gene (Patent Literature 4) has been reported as a method of predicting the therapeutic effectiveness of infliximab on rheumatoid arthritis. Furthermore, a method of comprehensively analyzing genetic polymorphisms (Patent literature 5) has been reported as a method of predicting the therapeutic effectiveness of an anti-TNF- ⁇ agent such as etanercept, adalimumab, or infliximab on rheumatoid arthritis.
- Patent literature 5 a method of predicting the therapeutic effectiveness of an anti-TNF- ⁇ agent such as etanercept, adalimumab, or infliximab on rheumatoid arthritis.
- the objective of the present invention is to provide a method of predicting and determining a therapeutic effect (level of improvement in a symptom or possibility of remission) prior to administration of a biological formulation, which is simple and cost-effective, highly versatile and highly accurate. Further objective of the present invention is to provide a diagnostic agent for carrying out the above-described method.
- the inventors have analyzed the prognostic state of a rheumatoid arthritis patient administered with the biological formulation and the concentrations of cytokines , chemokines and soluble receptors thereof in a serum of the patient prior to administration of the biological formulation in order to solve the problem to discover that a therapeutic effect on a rheumatoid arthritis patient (e.g., level of improvement in a symptom or possibility of remission) can be predicted and determined in a simple and cost-effective manner at any facility with high accuracy, prior to administering a biological formulation targeting an inflammatory cytokine by utilizing the serum concentration of one or more types selected from the group consisting of sgp130, IP-10, sTNFRI, sTNFRII, GM-CSF, IL-1 ⁇ , IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, Eotaxin, VEGF, MCP-1, T
- Item 1 A method of predicting and determining a therapeutic effect of a biological formulation targeting an inflammatory cytokine on a rheumatoid arthritis patient, characterized in comprising the step of measuring a concentration of at least one type of determination marker selected from the group consisting of sgp130, IP-10, sTNFRI, sTNFRII, GM-CSF, IL-1 ⁇ , IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, Eotaxin, VEGF, MCP-1, TNF- ⁇ , IFN- ⁇ , FGFbasic, PDGF-bb, sIL-6R, and MIP-1 ⁇ in a serum collected from the rheumatoid arthritis patient prior to the administration of the biological formulation.
- a concentration of at least one type of determination marker selected from the group consisting of sgp130, IP-10, sTNFRI, sTNFRI
- a therapeutic effect on a rheumatoid arthritis patient can be accurately estimated, and whether rheumatoid arthritis would enter a state of complete remission due to a biological formulation can be determined with high precision, prior to the administration of the biological formulation targeting an inflammatory cytokine.
- a level of improvement in a symptom for a rheumatoid arthritis patient can be accurately determined prior to the administration of the biological formulation, thus allowing the establishment of a suitable treatment plan, which takes into consideration the therapeutic effect of the biological formulation.
- the most effective treatment plan can be established for each patient by selecting the optimal biological formulation for each patient.
- the present invention is beneficial in terms of medical cost containment, sense of security from the prediction of a therapeutic effect and the like.
- the present invention enables the establishment of a suitable treatment plan based on an accurate prediction of effectiveness of a biological formulation.
- the present invention does not require complex and time-consuming genetic analysis which lacks versatility.
- the present invention uses the concentration of a specific cytokine, chemokine, and/or soluble receptor in a serum as an indicator.
- the present invention can estimate in advance the effectiveness of a biological formulation targeting an inflammatory cytokine for each patient in a simple and cost-effective manner by using an existing method of measurement.
- the present invention is a method of determining a therapeutic efficacy of a biological formulation targeting an inflammatory cytokine on a rheumatoid arthritis patient, characterized in comprising the step of measuring a concentration of one or more types selected from the group consisting of sgp130, IP-10, sTNFRI, sTNFRII, GM-CSF, IL-1 ⁇ , IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, Eotaxin, VEGF, MCP-1, TNF- ⁇ , IFN- ⁇ , FGFbasic, PDGF-bb, sIL-6R, and MIP-1 ⁇ in a serum collected from the rheumatoid arthritis patient prior to the administration of the biological formulation.
- a concentration of one or more types selected from the group consisting of sgp130, IP-10, sTNFRI, sTNFRII, GM-
- the determining method of the present invention is a method of predicting and determining a therapeutic effect of a biological formulation targeting an inflammatory cytokine on a rheumatoid arthritis patient.
- a biological formulation targeting an inflammatory cytokine is not particularly limited as long as it is a biological formulation used in rheumatoid arthritis therapy. A therapeutic effect can be predicted and determined in accordance with the type of biological formulation to be used in the determining method of the present invention.
- Examples of a biological formulation targeting an inflammatory cytokine include anti-IL-6 agents, anti-TNF- ⁇ agents and the like.
- Specific examples of anti-IL-6 agent include humanized anti-IL-6 receptor antibodies, anti-TNF- ⁇ antibodies, human soluble TNF/LT ⁇ receptors consisting of an Fc region of human IgG1 and a subunit dimer of an extracellular domain of a human tumor necrosis factor receptor II, and the like.
- humanized anti-IL-6 receptor antibodies include tocilizumab. Further, examples of the human soluble TNF/LT ⁇ receptors more specifically include etanercept. Further, examples of the anti-TNF- ⁇ antibodies more specifically include adalimumab and infliximab.
- Examples of optimal biological formulations thereamong which are applied in the determining method of the present invention include humanized anti-IL-6 receptor antibodies and humanized soluble TNF/LT ⁇ receptors, and still preferably tocilizumab and etanercept.
- the determining method of the present invention determines whether administration of a biological formulation is effective in a rheumatoid arthritis patient prior to administration of the biological formulation.
- target rheumatoid arthritis patients in the determining method of the present invention are not particularly limited, as long as it is prior to administration of the biological formulation.
- DMARDs such as methotrexate
- past dosing history of anti-cytokine therapy administration of infliximab etanercept, adalimumab, tocilizumab or the like
- a therapeutic effect due to a biological formulation can be predicted and determined by selecting a desired determination marker in accordance with the past dosing history of the biological formulation in the determining method of the present invention.
- the determining method of the present invention uses one or two or more types of determination markers selected from the group consisting of sgp130 (soluble gp130), IP-10 (interferon-inducible protein 10), sTNFRI (soluble receptors for tumor necrosis factor type I), sTNFRII (soluble receptors for tumor necrosis factor type II), GM-CSF (granulocyte macrophage colony-stimulating factor), IL-1 ⁇ (interleukin-1 ⁇ ), IL-2 (interleukin-2), IL-5 (interleukin-5), IL-6 (interleukin-6), IL-7 (interleukin-7), IL-8 (interleukin-8), IL-9 (interleukin-9), IL-10 (interleukin-10), IL-12 (interleukin-12), IL-13 (interleukin-13), IL-15 (interleukin-15), Eotaxin, VEGF (vascular endothelial growth factor), MCP-1 (monocyte chemotactic protein-1), TNF-
- One type of the aforementioned specific cytokine, chemokine, and soluble receptor may be used alone as a determination marker in the determining method of the present invention. However, it is preferable to use two or more types from thereamong in combination as a determination marker, from the viewpoint of predicting and determining a therapeutic effect due to a biological formulation at a higher precision.
- the determination marker is appropriately selected and used, depending on the therapeutic effect to be predicted and determined, type of biological formulation to be administered, past dosing history of biological formulation or the like. Specific optimal examples of determination marker are shown below for each therapeutic effect to be predicted and determined.
- level of improvement in symptom after therapy (level of improvement in value of disease activity indicator; value of disease activity indicator prior to therapy - value of disease activity indicator after therapy) is predicted and determined for biological formulation>
- a naive patient administered with tocilizumab (hereinafter, also referred to as an "tocilizumab therapy naive patient")
- at least one type selected from the group consisting of IL-7, IL-8, IL-12, IL-13, IP-10, VEGF, IL-1 ⁇ , TNF- ⁇ , and sIL-6R as a determination marker. It is more preferable to use IL-1 ⁇ , IL-7, TNF- ⁇ , and sIL-6R in combination as a determination marker.
- a switch patient administered with tocilizumab (hereinafter, also referred to as a "tocilizumab therapy switch patient”), it is preferable to use at least one type selected from the group consisting of IL-1 ⁇ , IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, FGFbasic, GM-CSF, IFN- ⁇ , TNF- ⁇ , and VEGF as a determination marker.
- etanercept therapy naive patient For a naive patient administered with etanercept (hereinafter, also referred to as an "etanercept therapy naive patient"), it is preferable to use at least one type selected from the group consisting of IL-6, IP-10, IL-2, IL-13, IL-15, sIL-6R, and sTNFRI as a determination marker. It is more preferable to use a combination of IL-2, IL-15, sIL-6R, and sTNFRI as a determination marker.
- a tocilizumab therapy naive patient it is preferable to use at least one type selected from the group consisting of sgp130, IL-8, Eotaxin, IP-10, sTNFRI, sTNFRII, IL-6, and VEGF as a determination marker. It is more preferable to use a combination of sgp130, IL-8, Eotaxin, IP-10, sTNFRI, sTNFRII, and IL-6, or a combination of sgp130, IL-8, Eotaxin, IP-10, sTNFRI, sTNFRII, IL-6, and VEGF as a determination marker.
- a tocilizumab therapy switch patient it is preferable to use at least one type selected from the group consisting of sgp130, IL-1 ⁇ , IL-2, IL-5, IL-15, GM-CSF, IFN- ⁇ , TNF- ⁇ , and IP-10 as a determination marker. It is more preferable to use a combination of sgp130, IP-10, and GM-CSF as a determination marker.
- IL-9 IL-9
- IL-6 IL-13
- TNF- ⁇ TNF- ⁇
- VEGF vascular endothelial growth factor
- tocilizumab For patients administered with tocilizumab (including both tocilizumab therapy naive patients and tocilizumab therapy switch patients), it is preferable to use at least one type selected from the group consisting of sgp130, IP-10, sTNFRII, IL-6, IL-7, MCP-1 and IL-1 ⁇ as a determination marker. It is more preferable to use at least sgp130, and even more preferable to use a combination of (i) sgp130, (ii) IP-10, (iii) sTNFRII, and (iv) IL-6, IL-7, MCP-1 or IL-1 ⁇ .
- a combination of (i) sgp130, (ii) IP-10, (iii) sTNFRII, and (iv) IL-6, IL-7, MCP-1 or IL-1 ⁇ is especially preferable as a determination marker.
- a combination of (i) sgp130, (ii) IP-10, (iii) sTNFRII, and (iv) IL-6 or IL-1 ⁇ is especially preferable as a determination marker.
- IL-9 IL-9
- TNF- ⁇ IL-9
- VEGF vascular endothelial growth factor
- PDGF-bb vascular endothelial growth factor
- MIP-1 ⁇ a determination marker
- cytokines, chemokines, and soluble receptors used as a determination marker can be measured by a measurement system utilizing an antigen-antibody reaction such as ELISA.
- ELISA antigen-antibody reaction
- Such measuring kits are commercially available.
- the cytokines , chemokines, and soluble receptors can be measured with a known measuring kit by a known method in the determining method of the present invention.
- a therapeutic effect due to a biological formulation can be predicted and determined based on a measured value of the determination marker.
- the prediction and determination include a method in which the determination marker is measured in advance for patients in full remission and patients who are not in remission from therapy with a biological formulation; a regression equation of a measured value of the determination marker (explanatory variable) and a therapeutic effect of biological formulation (objective variable) are found by regression analysis; and a measured value of a determination marker of a rheumatoid arthritis patient targeted for determination is applied to said regression equation.
- a value of serum concentration ( ⁇ g/ml) is preferably used. Further, it is preferable that a regression equation is derived by multiple regression analysis. The objective variable in the above-described regression equation may be appropriately determined based on the therapeutic effect to be predicted and determined.
- the objective variable when predicting and determining the level of improvement in a symptom after therapy for a biological formulation, the objective variable may be set to "a value obtained by subtracting a value of a disease activity indicator after a predetermined period of therapy from a value of a disease activity indicator prior to therapy" for analysis by multiple linear regression analysis.
- the objective variable when predicting and determining a value of a disease activity indicator after therapy for a biological formulation, the objective variable may be set to "a value of disease activity indicator after a predetermined period of therapy" for analysis by multiple linear regression analysis.
- a value of a disease activity indicator examples include a DAS (Disease activity score)-28 value, CDAI (Clinical Disease Activity Index) value, SDAI (Simple Disease Activity Index) value and the like.
- a DAS-28 value, CDAI value and SDAI value are correlated with one another and reflect a symptom of rheumatoid arthritis.
- any of such disease activity indicator values may be used in the determining method of the present invention.
- a disease activity indicator used in the determining method of the present invention is not limited to those exemplified above. Indicators that may be newly advocated in the future can be used.
- multiple logistic regression analysis may be used for analysis.
- a value of a disease activity indicator prior to therapy (DAS-28 value, CDAI value, SDAI value or the like) or a result of evaluation by a Boolean method may be utilized as an explanatory variable.
- determining method of the present invention should not be interpreted to be limited to the following specific methods.
- a level of improvement in a symptom after therapy due to a biological formulation can be predicted and determined by multiple linear regression analysis while setting an objective variable as "a value obtained by subtracting a value of a disease activity indicator after a predetermined period of therapy from a value of a disease activity indicator prior to therapy" and an explanatory variable as "a measured value of the determination marker".
- equations (1) and (2) have been discovered as regression equations for predicting and determining a level of improvement in a symptom after 16 weeks of therapy due to a biological formulation (level of improvement in DAS-28 value; DAS-28 value prior to therapy - DAS-28 value after 16 weeks of therapy), separated by the past dosing history of a rheumatoid arthritis patient and type of biological formulation.
- a level of improvement in a symptom after 16 weeks of therapy can be predicted and determined by finding an objective variable from applying values to one of the following regression equations (1) and (2) depending on the past dosing history of a rheumatoid arthritis patient subjected to determination and type of biological formulation.
- a level of improvement in a symptom due to a biological formulation is predicted and determined to be large for the patient for larger values of the objective variable calculated by the following regression equation.
- the regression equations (1) and (2) demonstrate an example of a regression equation used to predict and determine a level of improvement in DAS-28 value after 16 weeks of therapy due to a biological formulation.
- a level of improvement in a CDAI value or an SDAI value after 16 weeks of therapy due to a biological formulation can naturally be predicted and determined by multiple linear regression analysis by the same method using a CDAI value or SDAI value.
- regression equations for predicting and determining a level of improvement in a symptom after 16 weeks of therapy are shown in the above-described regression equations (1) and (2).
- a level of improvement in a symptom before or after 16 weeks of therapy due to the biological formulations can be predicted and determined by multiple linear regression analysis using the same method.
- equations (3)-(7) have been discovered as regression equations for predicting and determining a DAS-28 value of a symptom after 16 weeks of therapy due to a biological formulation, separated by the past dosing history of a rheumatism patient and type of biological formulation.
- a DAS-28 value after 16 weeks of therapy can be predicted and determined by finding an objective variable from applying values to one of the following regression equations (3)-(7), depending on the past dosing history of a rheumatoid arthritis patient subjected to determination and type of biological formulation.
- the objective variable calculated by the following regression equation is 2.3 or less, the patient is predicted and determined to reach remission due to a biological formulation.
- regression equation (7) does not use a DAS-28 value prior to etanercept administration as an explanatory variable, a DAS-28 value after 16 weeks of therapy can be predicted while eliminating a subjective opinion of a physician. Thus, regression equation (7) is considered preferable over regression equation (6).
- the regression equations (3)-(7) show examples of a regression equation used to predict and determine a DAS-28 value after 16 weeks of therapy due to a biological formulation.
- a CDAI value or SDAI value itself after 16 weeks of therapy due to a biological formulation can naturally be predicted and determined by multiple linear regression analysis by the same method using a CDAI value or SDAI value.
- regression equations for predicting and determining a value of a disease activity indicator after 16 weeks of therapy are shown in the above-described regression equations (3)-(7).
- a value of disease activity indicator prior to or after 16 weeks of therapy due to the biological formulations can naturally be predicted and determined by multiple linear regression analysis using the same method.
- equations (8)-(16) have been discovered as regression equations for predicting and determining the possibility of remission (either remission or not in remission) after 16 weeks of therapy due to a biological formulation, separated by the past dosing history of a rheumatoid arthritis patient and type of biological formulation. It is possible to predict and determine whether remission is reached after 16 weeks of therapy by finding the probability (p) of remission after 16 weeks of therapy from applying values to one of the following regression equations (8)-(16) depending on the past dosing history of a rheumatoid arthritis patient subjected to determination and type of biological formulation.
- the probability of remission estimated from the following regression equations (8) - (16) refers to the probability of a DAS-28 value being 2.3 or less.
- a p value computed from regression equations (8)-(16) closer to 1 indicates a higher possibility of remission after 16 weeks of therapy.
- the p value of 0.5 or higher can predict and determine remission and less than 0.5 can predict and determine no remission for convenience's sake.
- a DAS-28 value of 2.3 is used as the boundary between remission and non-remission to enhance the precision of prediction and determination of remission because a CRP value tends to decrease and DAS-28 value may decreases regardless of inflammation by inhibiting IL-6.
- the value is set at a lower value of DAS-28 value (2.6), which is generally considered the boundary between remission and non-remission.
- Determination markers VEGF and PDGF-bb, DAS-28 value prior to etanercept administration is also used as an explanatory variable.
- p / 1 ⁇ p exp ⁇ 19.058 + 1.390 ⁇ a + ⁇ 2.763 ⁇ E + 4.962 ⁇ Q
- regression equation (16) does not use a DAS-28 value prior to etanercept administration as an explanatory variable, the possibility of remission can be predicted while eliminating a subjective opinion of a physician. Thus, regression equation (16) is considered preferable over regression equations (14) and (15).
- the regression equations (6)-(16) show examples of a regression equation for predicting and determining the possibility of remission after 16 weeks of therapy, with a DAS-28 value after 16 weeks of therapy of 2.3 or lower considered remission and the value over 2.3 as non-remission.
- the possibility of remission after 16 weeks of therapy due to a biological formulation can naturally be predicted and determined by multiple logistic regression analysis with the same method using a CDAI value or SDAI value.
- regression equations for predicting and determining the possibility of remission after 16 weeks of therapy are shown in the above-described regression equations (6) - (16).
- the possibility of remission prior to or after 16 weeks of therapy due to a biological formulation can be predicted and determined by multiple logistic regression analysis using the same method.
- the determining method of the present invention can predict the therapeutic effectiveness of a biological formulation prior to the administration thereof.
- the method can be utilized in selecting the optimal biological formulation that should be administered prior to starting therapy.
- cases in which tocilizumab is administered and cases in which etanercept is administered are each predicted by the aforementioned method and a biological formulation with a higher level of improvement is selected, so that an optimal biological formulation can be administered to the patient.
- a level of improvement in a symptom after therapy with tocilizumab therapy which is predicted by using regression equation (1) is compared to a level of improvement in a symptom after therapy with etanercept therapy, which is predicted by using regression equation (2), so that the biological formulation with a higher level of improvement can be selected as the optimal biological formulation.
- a DAS-28 value after 16 weeks of therapy of a naive patient cases in which tocilizumab is administered and cases in which etanercept is administered are each predicted by the aforementioned method and a biological formulation with a lower DAS-28 value after 16 weeks of therapy is selected so that an optimal biological formulation can be administered to the patient.
- a DAS-28 value after 16 weeks of therapy with tocilizumab therapy which is predicted by using one of regression equations (3)-(5) is compared to a DAS-28 value after 16 weeks of therapy with etanercept therapy, which is predicted by using regression equation (6) or (7), so that the biological formulation with a smaller DAS-28 value can be selected as the optimal biological formulation.
- cases in which tocilizumab is administered and cases in which etanercept is administered are each predicted by the aforementioned method to select a biological formulation with a higher possibility of remission, so that the optimal biological formulation can be administered to the patient.
- the possibility of remission with tocilizumab therapy which is predicted by using one of regression equations (8) - (11)
- the possibility of remission which is predicted by using one of regression equations (14)-(16)
- the biological formulation with a higher possibility of remission can be selected as the optimal biological formulation.
- the diagnostic agent of the present invention is a diagnostic agent for determining the effectiveness of therapy due to a biological formulation targeting an inflammatory cytokine for a rheumatoid arthritis patient, characterized by comprising a reagent capable of detecting at least one type of determination marker selected from the group consisting of sgp130, IP-10, sTNFRI, sTNFRII, GM-CSF, IL-1 ⁇ , IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, Eotaxin, VEGF, MCP-1, TNF- ⁇ , IFN- ⁇ , FGFbasic, PDGF-bb, sIL-6R, and MIP-1 ⁇ .
- the determination marker can be measured by a measurement system utilizing an antigen-antibody reaction such as ELISA.
- an antigen-antibody reaction such as ELISA.
- reagents capable of detecting the determination marker include antibodies that can specifically bind to the determination marker and fragments thereof. Further, antibodies that can specifically bind to the determination marker may be bound on a suitable support to be provided as an antibody array.
- the diagnostic agent of the present invention may comprise a reagent (secondary antibody, color producing substance or the like) required for detecting the determination marker by an antigen-antibody reaction.
- a reagent secondary antibody, color producing substance or the like
- a rheumatism patient who has not received anti-cytokine therapy administration of infliximab, etanercept, adalimumab, tocilizumab or the like
- a switch patient a rheumatism patient who has received anti-cytokine therapy in the past.
- 155 rheumatoid arthritis patients to whom methotrexate therapy was ineffective, were registered at the Higashihiroshima Memorial Hospital from March 2008 to June 2013.
- 98 patients received therapy with tocilizumab and the remaining 57 patients received therapy with etanercept.
- 58 patients were naive patients who had not previously received anti-cytokine therapy and 40 patients were switch patients who had previously received anti-cytokine therapy 1-3 times.
- 49 patients were naive patients who had not previously received anti-cytokine therapy, and the remaining 8 patients were switch patients who had previously received anti-cytokine therapy.
- Informed consent was obtained prior to receiving a blood sample supply from all patients. Further, the tests were conducted with permission prior to the study from the ethics committee of the Higashihiroshima Memorial Hospital.
- Table 1 shows the clinical baseline individual group statistics for group of individuals and clinical diagnosis. Further, Figure 1 shows a trial profile of patients receiving therapy with tocilizumab and patients receiving therapy with etanercept. Figures 2-1 to 2-4 show serum concentration of cytokine/chemokine/soluble receptor prior to therapy. 9 na ⁇ ve patients (8 patients who suffered from side effects or other diseases and 1 patient for whom data could not be obtained for the entire 16 weeks) among patients treated with tocilizumab were eliminated. Further, 1 switch patient suffering from a side effect (patient for whom data could not be obtained for the entire 16 weeks) among patients treated with tocilizumab was eliminated.
- cytokines In order to create a baseline concentration of cytokines, serum was collected from healthy individuals (56 individual; 20 males and 36 females) without a history of suffering from hepatitis C or cancer. The healthy individuals underwent medical examination by the Louis Pasteur Center for Medical Research or the Higashihiroshima Memorial Hospital and informed consent was received in writing from the healthy individuals. The baseline concentration was used to find a distribution pattern of cytokines/chemokines/soluble receptors.
- cytokines Prior to therapy, concentrations of cytokines, chemokines, and soluble receptors in the serum of rheumatoid arthritis patients were measured.
- Figure 1 shows clinical results for naive patients and switch patients administered with 8 mg/kg tocilizumab or 50 mg/kg etanercept once every 4 weeks. After 16 weeks of therapy (after 4 administrations), a therapeutic effect was determined based on DAS-28-CRP values and whether the patient is in remission or non-remission. Results for non-remission were further classified into low, medium and high based on DAS-28-CRP values of the patients. DAS-28-ESR values are extensively used to determine the symptom of rheumatoid arthritis patients. However, it is reported that DAS-28-CRP values are almost interchangeable with DAS-28-ESR values and the same results are derived therefrom ( Ann Rheum Dis. 2007, March 407-409 Comparison of Disease Activity Score (DAS)28-erythrocyte Sedimentation rate and DAS-C-reactive protein threshold votes. Inoue E, Yamanaka H , et al.)
- Figure 3 shows detailed clinical results of each patient shown in Figure 1 , i.e., results of determining DAS-28-CRP values prior to therapy and after 16 weeks of therapy for naive patients who received tocilizumab therapy, switch patients who received tocilizumab therapy, and naive patients who received etanercept therapy.
- DAS-28-CRP values may be denoted simply as DAS-28 values.
- cytokine array system Bio-Plex 200, Bio-Rad Laboratories
- Serum for all patients and healthy individuals were collected by 10 minutes of centrifugation (1600xg). All serum samples were stored at -80° C.
- Bio-Plex Human Cytokine 27-Plex Panel is configured such that 27 types of cytokines (IL-1 ⁇ , IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, basic FGF, eotaxin, G-CSF, GM-CSF, IFN- ⁇ , IP-10, MCP-1, MIP-1 ⁇ , MIP-1 ⁇ , PDGF-bb, RANTES, TNF- ⁇ , and VEGF) can be analyzed.
- cytokines IL-1 ⁇ , IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, basic FGF, eotaxin, G-CSF, GM-CSF, IFN- ⁇ , IP-10, M
- sIL-6R sgp130
- sTNF-RI sTNF-RII
- sTNF-RII concentrations of cytokines, chemokines, and soluble receptors of 56 healthy individuals were simultaneously measured to find the distribution patterns thereof.
- Bio-Plex Manager software version 5.0 was used to conduct data collection and analysis.
- cytokine/chemokine values were analyzed.
- concentration ( ⁇ g/ml) were directly used for sgp130.
- Tables 1 and 2 show clinical baseline individual group statistics, clinical diagnosis and cytokine/chemokine/soluble receptor characteristics.
- Figures 2-1 to 2-4 shows clinical baseline individual group statistics for healthy individuals and rheumatoid arthritis patients with respect to serum concentrations of cytokines/chemokines/soluble receptors prior to therapy.
- Stage and Class are results of determination with respect to functional classification criteria for rheumatoid arthritis based on Steinbrocker (1949) classification (I-IV; Steinbrocker O et al: Therapeutic criteria in rheumatoid arthritis.
- Figure 4 shows the relationship between a DAS-28 value prior to therapy and a value obtained from subtracting a DAS-28 value after 16 weeks from the DAS-28 value prior to therapy (PreDAS-28score - 16W DAS-28 score) in a naive patient who has received tocilizumab therapy (PreDAS-28 score). According to Figure 4 , improvement in DAS-28 values was observed after tocilizumab therapy in most naive patients.
- naive patients and about 23% of switch patients are expected to exhibit remission after tocilizumab therapy.
- the final symptoms are not identical, some improvement in the symptom is observed in about 45% of naive patients and about 77% of switch patients. Further, about 36.7% of naive patients are expected to exhibit remission after etanercept therapy. In addition, some improvement in the symptom is observed after etanercept therapy in about 60% of the remaining patients.
- Figures 2-1 to 2-4 show comparisons of baseline individual group statistics of cytokines/chemokines/soluble receptors prior to therapy for healthy individuals and three groups (naive patients who received tocilizumab therapy, switch patients who received tocilizumab therapy, naive patients who received etanercept therapy).
- serum concentration other than those for sgp130, sIL-6R and sTNFRI in rheumatoid arthritis patients were significantly higher in comparison to healthy individuals.
- serum concentrations of cytokines/chemokines were lower in naive patients who received etanercept therapy in comparison to naive patients who received tocilizumab therapy.
- logIL-1 ⁇ , logIL-5, logIL-6, logIL-7, logIL-10, logIL-12, logIL-13, logIL-15, logFGF, logGM-CSF, logIFN- ⁇ , logTNF- ⁇ and logVEGF significantly matched the level of improvement in DAS-28 values.
- logIL-6 and logIP-10 significantly matched the level of improvement in DAS-28 values for naive patients who receivedetanercept therapy.
- logIL-1 ⁇ , logIL-2, logIL-5, logIL-15, logGM-CSF, logIFN- ⁇ , logTNF- ⁇ and sgp130 significantly matched DAS-28 values after 16 weeks of therapy.
- logIL-9 significantly matched DAS-28 values after 16 weeks of therapy for na ⁇ ve patients who received etanercept therapy.
- regression equation (4) found based on the multiple linear regression analysis shown in Table 7 was used to find a predicted value of DAS-28 value after 16 weeks of therapy in naive patients who received tocilizumab therapy.
- Figure 5 shows the results of comparing predicted values of DAS-28 values after 16 weeks of therapy calculated by regression equation (4) and actual values of DAS-28 values after 16 weeks of therapy. It was confirmed from the results that DAS-28 values after 16 weeks of therapy estimated from the results of multiple linear regression analysis shown in Table 7 are very consistent with actual values of DAS-28 values after 16 weeks of therapy.
- regression equation (5) found based on the multiple linear regression analysis shown in Table 8 was used to find a predicted value of DAS-28 value after 16 weeks of therapy in switch patients who received tocilizumab therapy.
- Figure 6 shows the results of comparing the predicted values of DAS-28 values after 16 weeks of therapy calculated by regression equation (5) and actual values of DAS-28 values after 16 weeks of therapy. It was confirmed from the results that DAS-28 values after 16 weeks of therapy estimated from the results of multiple linear regression analysis shown in Table 8 are very consistent with actual values of DAS-28 values after 16 weeks of therapy.
- Regression equation (7) found based on the multiple linear regression analysis shown in Table 10 was used to find a predicted value of DAS-28 value after 16 weeks of therapy in naive patients who received etanercept therapy.
- Figure 7 shows the results of comparing predicted values of DAS-28 values after 16 weeks of therapy calculated by regression equation (7) and actual values of DAS-28 values after 16 weeks of therapy. It was confirmed from the results that DAS-28 values after 16 weeks of therapy can be estimated to a certain extent from the results of multiple linear regression analysis shown in Table 10.
- naive patients who received etanercept therapy are classified into patients who are predicted to have a higher therapeutic effect when receiving tocilizumab therapy ( Figure 8 a ), patients who are predicted to have barely any difference observed between etanercept therapy and tocilizumab therapy ( Figure 8 b ), and patients who are predicted to have a higher therapeutic effect observed when receiving etanercept therapy ( Figure 8 c ).
- tocilizumab therapy is estimated to be more effective than etanercept therapy that was actually received.
- a more effective therapeutic agent can be selected by estimating DAS-28 values due to tocilizumab therapy and etanercept therapy prior to therapy by the present invention.
- Table 10 shows the results of analyzing data for cytokine/chemokine/soluble receptor concentrations for naive patients and switch patients who received tocilizumab therapy and naive patients who received etanercept therapy. It was found by simple logistic regression analysis that swollen joint count and tender joint count and DAS-28 values were significantly different between complete remission and non-remission groups. Furthermore, sgp130 was significantly different between complete remission and non-remission groups in naive and switch patients who received tocilizumab therapy (Table 11) .
- Figure 9 shows the results of analyzing the relationship between serum sgp130 concentration and DAS-28 value prior to therapy for remission and non-remission patients. As is clear from Figure 9 , many patients who have reached remission had a high sgp130 concentration.
- a multivariable model was examined as a prediction biomarker for remission and non-remission by phased multiple forward logistic regression analysis based on serum concentration of cytokines/chemokines/soluble receptors in patients prior to administration of tocilizumab.
Abstract
Description
- The present invention relates to a method of predicting and determining a therapeutic effect of a biological formulation on a rheumatoid arthritis patient. More specifically, the present invention relates to a method of predicting and determining a therapeutic effect, such as the level of improvement in a symptom or the possibility of remission, prior to the administration of a biological formulation to a rheumatoid arthritis patient. Furthermore, the present invention relates to a diagnostic agent for predicting and determining a therapeutic effect due to a biological formulation on a rheumatoid arthritis patient.
- Rheumatoid arthritis is a systemic inflammatory disease, which is predominantly a lesion in the articular synovial membrane. It is estimated that approximately 700,000 people suffer from rheumatoid arthritis in Japan. Many biological formulations that target inflammatory cytokines have been developed for rheumatoid arthritis therapy. In recent years, anti-TNF-α agents or anti-IL-6 agents, which inhibit TNF-α or IL-6 action, have been used in clinical practices.
- Conventionally, biological formulations targeting an inflammatory cytokine, such as tocilizumab, etanercept, adalimumab, or infliximab, have been used in rheumatoid arthritis therapy. Tocilizumab is a humanized IL-6 receptor antibody, which is an agent that causes rheumatoid arthritis to subside by the action of binding to a membrane-binding IL-6 receptor and a soluble IL-6 receptor to suppress IL-6 signaling. Further, etanercept is a fully human soluble TNF/LTα receptor formulation consisting of a subunit dimer of an extracellular domain of a human tumor necrosis factor II receptor and an Fc region of a human IgG1. Etanercept is an agent that binds to both TNFα/β to inhibit signaling to a TNF receptor to cause rheumatoid arthritis to subside. Adalimumab and infliximab are human and chimeric TNF-α antibodies, which are agents that cause rheumatoid arthritis to subside by specifically binding to excessively produced TNF-α and inhibiting the binding of TNF-α to a TNF-α receptor.
- For such biological formulations, a certain level of effectiveness in rheumatoid arthritis therapy is verified, while such formulations have disadvantages such as the formulations being expensive and time-intensive for determining a therapeutic effect. In addition, there are certain percentages of cases with no effect, and expression of side effects, such as an infectious disease or an interstitial pneumonia, has been observed in some cases. For this reason, cases where the biological formulation is usable are limited. Thus, if the effectiveness of a biological formulation targeting an inflammatory cytokine can be estimated in advance for each rheumatoid arthritis patient, this would be a boon to rheumatoid arthritis patients and provide contribution to medical business.
- Markers for predicting the effectiveness of a biological formulation targeting an inflammatory cytokine on a rheumatoid arthritis patient have been intensively investigated. For example, a method of using a microDNA chip, a method of using a CRP value at baseline as an indicator, a method of using blood soluble ICAMI concentration and CXCL13 concentration as indicators, a method of using leukocyte ADAMT5 gene expression amount as an indicator (Non Patent Literature 4), a method of comprehensively analyzing genetic polymorphisms (
Patent Literatures 1 and 2), a method of analyzing a genetic mutation of an IL-6 receptor (Patent Literature 3) and the like have been reported as a method of predicting the therapeutic effectiveness of tocilizumab on rheumatoid arthritis. Further, a method of analyzing the IL10RB gene, the IRF5 gene, and polymorphisms of the IRF5 gene (Patent Literature 4) has been reported as a method of predicting the therapeutic effectiveness of infliximab on rheumatoid arthritis. Furthermore, a method of comprehensively analyzing genetic polymorphisms (Patent literature 5) has been reported as a method of predicting the therapeutic effectiveness of an anti-TNF-α agent such as etanercept, adalimumab, or infliximab on rheumatoid arthritis. - However, conventional methods of determining a therapeutic effect on rheumatoid arthritis have disadvantages such as: genetic analysis or the like is required, in addition to the operation being complicated; analysis is time and cost-intensive; there is little versatility; proper diagnosis rate is low; and the like. Furthermore, conventional approaches cannot accurately determine whether rheumatoid arthritis can be in full remission prior to the administration of a biological formulation. Thus, conventional approaches have a problem in that an appropriate therapeutic plan which takes into consideration the therapeutic effect thereof cannot be established prior to administration of a biological formulation.
- Such background conventional techniques elicit a desire for the establishment of a technique for predicting a therapeutic effect of biological formulation administration to a rheumatoid arthritis patient, which is simple and cost-efficient, highly versatile and highly accurate.
-
- [PTL 1] International Publication No.
WO 2011/128096 - [PTL 2]
Japanese Laid-Open Publication No. 2011-182780 - [PTL 3] International Publication No.
WO 2012/41332 - [PTL 4]
Japanese Laid-Open Publication No. 2009-225713 - [PTL 5]
Japanese Laid-Open Publication No. 2010-088432 - The objective of the present invention is to provide a method of predicting and determining a therapeutic effect (level of improvement in a symptom or possibility of remission) prior to administration of a biological formulation, which is simple and cost-effective, highly versatile and highly accurate. Further objective of the present invention is to provide a diagnostic agent for carrying out the above-described method.
- The inventors have analyzed the prognostic state of a rheumatoid arthritis patient administered with the biological formulation and the concentrations of cytokines , chemokines and soluble receptors thereof in a serum of the patient prior to administration of the biological formulation in order to solve the problem to discover that a therapeutic effect on a rheumatoid arthritis patient (e.g., level of improvement in a symptom or possibility of remission) can be predicted and determined in a simple and cost-effective manner at any facility with high accuracy, prior to administering a biological formulation targeting an inflammatory cytokine by utilizing the serum concentration of one or more types selected from the group consisting of sgp130, IP-10, sTNFRI, sTNFRII, GM-CSF, IL-1β, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, Eotaxin, VEGF, MCP-1, TNF-α, IFN-γ, FGFbasic, PDGF-bb, sIL-6R, and MIP-1α.
- More specifically, the inventors have obtained the following knowledge.
- (1-1) It was discovered through simple linear regression analysis that when therapy is applied by administering tocilizumab to a rheumatism patient who has not received anti-cytokine therapy (administration of infliximab, etanercept, adalimumab, tocilizumab or the like) in the past (may also be referred to as a "naïve patient" hereinafter), the level of improvement in the DAS-28 value (DAS-28 value prior to therapy - DAS-28 value after 16 weeks of therapy) is significantly correlated with the log values of serum concentrations of IL-7, IL-8, IL-12, IL-13, IP-10, and VEGF prior to the administration of tocilizumab to the patient.
- (1-2) It was discovered through simple linear regression analysis that when therapy is applied by administering tocilizumab to a rheumatism patient who has received anti-cytokine therapy in the past (also referred to as a "switch patient" hereinafter), the level of improvement in the DAS-28 value is significantly correlated with the log values of serum concentrations of IL-1β, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, FGFbasic, GM-CSF, IFN-γ, TNF-α, and VEGF prior to the administration of tocilizumab to the patient.
- (1-3) It was discovered through simple linear regression analysis that when therapy is applied by administering etanercept to a naive patient, the level of improvement in DAS-28 value is significantly correlated with the log values of serum concentrations of IL-6 and IP-10 prior to the administration of etanercept to the patient.
- (1-4) It was discovered through multiple linear regression analysis that when therapy is applied by administering tocilizumab to a naive patient, the level of improvement in DAS-28 value is significantly correlated with a combination of log values of serum concentrations of IL-1β, IL-7, TNF-α, and sIL-6R prior to the administration of tocilizumab to the patient.
- (1-5) It was discovered through multiple linear regression analysis that when therapy is applied by administering etanercept to a naive patient, the level of improvement in DAS-28 value is significantly correlated with a combination of log values of serum concentrations of IL-2, IL-15, sIL-6R, and sTNFRI prior to the administration of etanercept to the patient.
- (2-1) It was discovered through simple linear regression analysis that when therapy is applied by administering tocilizumab to a naive patient, the DAS-28 value after 16 weeks of therapy is significantly correlated with a serum concentration of sgp130 prior to the administration of tocilizumab to the patient.
- (2-2) It was discovered through simple linear regression analysis that when therapy is applied by administering tocilizumab to a switch patient, the DAS-28 value after 16 weeks of therapy is significantly correlated with the log values of serum concentrations of It-1β, IL-2, IL-5, IL-15, GM-CSF, IFN-γ, and TNF-α and a serum concentration of sgp130 prior to the administration of tocilizumab to the patient.
- (2-3) It was discovered through simple linear regression analysis that when therapy is applied by administering etanercept to a naive patient, the DAS-28 value after 16 weeks of therapy is significantly correlated with the log value of a serum concentration of IL-9 prior to the administration of etanercept to the patient.
- (2-4) It was discovered through multiple linear regression analysis that when therapy is applied by administering tocilizumab to a naive patient, the DAS-28 value after 16 weeks of therapy is significantly correlated with a combination of log values of serum concentrations of IL-8, Eotaxin, IP-10, sTNRFI, sTNFRII, IL-6 and VEGF and a serum concentration of sgp130 prior to the administration of tocilizumab to the patient.
- (2-5) It was discovered through multiple linear regression analysis that when therapy is applied by administering tocilizumab to a naive patient, the DAS-28 value after 16 weeks of therapy is significantly correlated with a combination of log values of serum concentrations of IL-8, Eotaxin, IP-10, sTNFRI, sTNRFII, and IL-6 and a serum concentration of sgp130 prior to the administration of tocilizumab to the patient.
- (2-6) It was discovered through multiple linear regression analysis that when therapy is applied by administering tocilizumab to a switch patient, the DAS-28 value after 16 weeks of therapy is significantly correlated with a combination of log values of serum concentrations of IP-10 and GM-CSF and a serum concentration of sgp130 prior to the administration of tocilizumab to the patient.
- (2-7) It was discovered through multiple linear regression analysis that when therapy is applied by administering etanercept to a naive patient, the DAS-28 value after 16 weeks of therapy is significantly correlated with a combination of log values of serum concentrations of IL-6 and IL-13 and the DAS-28 value prior to the administration of etanercept.
- (2-8) It was discovered through multiple linear regression analysis that when therapy is applied by administering etanercept to a naive patient, the DAS-28 value after 16 weeks of therapy is significantly correlated with a combination of log values of serum concentrations of IL-9, TNF-α, and VEGF prior to the administration of etanercept.
- (3-1) It was discovered through multiple logistic regression analysis that the possibility of remission, when therapy is applied by administering tocilizumab to a naïve patient can be predicted and determined by combining a serum concentration of sgp130, a log value of a serum concentration of IP-10, a log value of a serum concentration of sTNFRII, and a log value of a serum concentration of IL-6, IL-7, MCP-1, or IL-1β prior to the administration of tocilizumab.
- (3-2) It was discovered through multiple logistic regression analysis that the possibility of remission, when therapy is applied by administering tocilizumab to a switch patient, can be predicted and determined by combining a serum concentration of sgp130, a log value of a serum concentration of IP-10, a log value of a serum concentration of sTNFRII, and a log value of a serum concentration of IL-6 or IL-1β prior to the administration of tocilizumab.
- (3-3) It was discovered through multiple logistic regression analysis that the possibility of remission, when therapy is applied by administering etanercept to a naive patient, can be predicted and determined by combining the DAS-28 value and log values of serum concentrations of VEGF and PDGF-bb prior to the administration of etanercept.
- (3-4) It was discovered through multiple logistic regression analysis that the possibility of remission, when therapy is applied by administering etanercept to a naive patient, can be predicted and determined by combining the DAS-28 value and log values of serum concentrations of MIP-1α and PDGF-bb prior to the administration of etanercept.
- (3-5) It was discovered through multiple linear regression analysis that the possibility of remission, when therapy is applied by administering etanercept to a naive patient, can be predicted and determined by combining log values of serum concentrations of IL-9 and TNF-α prior to the administration of etanercept.
- The present invention was completed by additional repeated examinations based on such knowledge. Specifically, the present invention provides inventions in the following embodiments.
Item 1. A method of predicting and determining a therapeutic effect of a biological formulation targeting an inflammatory cytokine on a rheumatoid arthritis patient, characterized in comprising the step of measuring a concentration of at least one type of determination marker selected from the group consisting of sgp130, IP-10, sTNFRI, sTNFRII, GM-CSF, IL-1β, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, Eotaxin, VEGF, MCP-1, TNF-α, IFN-γ, FGFbasic, PDGF-bb, sIL-6R, and MIP-1α in a serum collected from the rheumatoid arthritis patient prior to the administration of the biological formulation. -
Item 2. The method ofitem 1 of predicting and determining a possibility of remission with tocilizumab, wherein
the determination marker is at least one type selected from the group consisting of sgp130, IP-10, sTNFRII, IL-6, IL-7, MCP-1, and IL-1β. -
Item 3. The method of determining ofitem 2, wherein at least sgp130 is used as the determination marker. -
Item 4. The method of determining ofitem
a patient to be administered with tocilizumab is a rheumatoid arthritis patient who has not received anti-cytokine therapy in the past, and
the determination marker is a combination of (i) sgp130, (ii) IP-10, (iii) sTNFRII, and (iv) IL-6, IL-7, MCP-1 or IL-1β.Item 5. The method of determining ofitem
a patient to be administered with tocilizumab is a rheumatoid arthritis patient who has received anti-cytokine therapy in the past, and
the determination marker is a combination of (i) sgp130, (ii) IP-10, (iii) sTNFRII, and (iv) IL-6 or IL-1β. -
Item 6. The method of determining ofitem 1, wherein
the method is a method of predicting and determining a possibility of remission with etanercept in a rheumatism patient who has not received anti-cytokine therapy in the past, and
the determination marker is at least one type selected from the group consisting of IL-9, TNF-α, VEGF, PDGF-bb, and MIP-1α.Item 7. The method of determining ofitem 6, wherein the determination marker is a combination of IL-9 and TNF-α, a combination of VEGF and PDGF-bb, or a combination of MIP-1α and PDGF-bb. -
Item 8. The method of determining ofitem 1, wherein
the method is a method of predicting and determining a disease activity indicator after therapy with tocilizumab in a rheumatism patient who has not received anti-cytokine therapy in the past, and
the determination marker is at least one type selected from the group consisting of sgp130, IL-8, Eotaxin, IP-10, sTNFRI, sTNFRII, IL-6, and VEGF. -
Item 9. The method of determining ofitem 8, wherein the determination marker is a combination of sgp130, IL-8, Eotaxin, IP-10, sTNFRI, sTNFRII, and IL-6 or a combination of sgp130, IL-8, Eotaxin, IP-10, sTNFRI, sTNFRII, IL-6 and VEGF. -
Item 10. The method of determining ofitem 1, wherein
the method is a method of predicting and determining a value of a disease activity indicator after therapy with tocilizumab in a rheumatism patient who has received anti-cytokine therapy in the past, and
the determination marker is at least one type selected from the group consisting of sgp130, IL-1β, IL-2, IL-5, IL-15, GM-CSF, IFN-γ, TNF-α, and IP-10. - Item 11. The method of determining of
item 10, wherein the determination marker is a combination of sgp130, IP-10, and GM-CSF. - Item 12. The method of determining of
item 1, wherein
the method is a method of predicting and determining a value of a disease activity indicator after therapy with etanercept in a rheumatism patient who has not received anti-cytokine therapy in the past, and
the determination marker is at least one type selected from the group consisting of IL-9, IL-6, IL-13, TNF-α, and VEGF.Item 13. The method of determining of item 12, wherein
the determination marker is a combination of IL-9, TNF-α and VEGF or a combination of IL-6 and IL-13. -
Item 14. The method of determining ofitem 1, wherein
the method is a method of predicting and determining a level of improvement in a symptom after therapy with tocilizumab in a rheumatism patient who has not received anti-cytokine therapy in the past, and
the determination marker is at least one type selected from the group consisting of IL-7, IL-8, IL-12, IL-13, IP-10, VEGF, IL-1β, TNF-α, and sIL-6R. -
Item 15. The method of determining ofitem 14, wherein the determination marker is a combination of IL-1β, IL-7, TNF-α, and sIL-6R. -
Item 16. The method of determining ofitem 1, wherein
the method is a method of predicting and determining a level of improvement in a symptom after therapy with tocilizumab in a rheumatism patient who has received anti-cytokine therapy in the past, and
the determination marker is at least one type selected from the group consisting of IL-1β, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, FGFbasic, GM-CSF, IFN-γ, TNF-α, and VEGF.Item 17. The method of determining ofitem 1, wherein
the method is a method of predicting and determining a level of improvement in a symptom after therapy with etanercept in a rheumatism patient who has not received anti-cytokine therapy in the past, and
the determination marker is at least one type selected from the group consisting of IL-6, IP-10, IL-2, IL-13, IL-15, sIL-6R, and sTNFRI. -
Item 18. The method of determining ofitem 17, wherein the determination marker is a combination of IL-2, IL15, sIL-6R, and sTNFRI or a combination of IL-6 and IL-13. - Item 19. A method of selecting a more effective biological formulation for therapy in a rheumatism patient who has not received anti-cytokine therapy in the past from among biological formulations consisting of tocilizumab and etanercept, comprising:
- predicting and determining a possibility of remission with tocilizumab in accordance with the method of determining of
item 4; - predicting and determining a possibility of remission with etanercept in accordance with the method of determining of
item 6; and - comparing the possibility of remission with tocilizumab with the possibility of remission with etanercept that were predicted and determined in the aforementioned steps to select a biological formulation with a high possibility of remission.
Item 20. A method of selecting a more effective biological formulation for therapy in a rheumatism patient who has not received anti-cytokine therapy in the past from among biological formulations consisting of tocilizumab and etanercept, comprising:- predicting and determining a disease activity indicator after therapy with tocilizumab in accordance with the method of determining of
item 10 or 11; - predicting and determining a disease activity indicator after therapy with etanercept in accordance with the method of determining of
item 12 or 13; and - comparing the disease activity indicator after therapy with tocilizumab with the disease activity indicator after therapy with etanercept that were predicted and determined in the aforementioned steps to select a biological formulation with a low disease activity indicator after therapy.
- predicting and determining a disease activity indicator after therapy with tocilizumab in accordance with the method of determining of
- predicting and determining a possibility of remission with tocilizumab in accordance with the method of determining of
-
Item 21. A method of selecting a more effective biological formulation for therapy in a rheumatism patient who has not received anti-cytokine therapy in the past from among biological formulations consisting of tocilizumab and etanercept, comprising:- predicting and determining a level of improvement in a symptom after therapy with tocilizumab in accordance with the method of determining of
item - predicting and determining a level of improvement in a symptom after therapy with etanercept in accordance with the method of determining of
item - comparing the level of improvement in a symptom after therapy with tocilizumab with the level of improvement in a symptom after therapy with etanercept that were predicted in the aforementioned steps to select a biological formulation with a high level of improvement in a symptom after therapy. Item 22. A diagnostic agent for predicting and determining a therapeutic effect due to a biological formulation targeting an inflammatory cytokine on a rheumatoid arthritis patient, comprising a reagent capable of detecting at least one type of marker selected from the group consisting of sgp130, IP-10, sTNFRI, sTNFRII, GM-CSF, IL-1β, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, Eotaxin, VEGF, MCP-1, TNF-α, IFN-γ, FGFbasic, PDGF-bb, sIL-6R, and MIP-1α.
- predicting and determining a level of improvement in a symptom after therapy with tocilizumab in accordance with the method of determining of
- Accordingly to the present invention, a therapeutic effect on a rheumatoid arthritis patient can be accurately estimated, and whether rheumatoid arthritis would enter a state of complete remission due to a biological formulation can be determined with high precision, prior to the administration of the biological formulation targeting an inflammatory cytokine. Furthermore, according to the present invention, a level of improvement in a symptom for a rheumatoid arthritis patient can be accurately determined prior to the administration of the biological formulation, thus allowing the establishment of a suitable treatment plan, which takes into consideration the therapeutic effect of the biological formulation. Further, according to the present invention, it is possible to predict which biological formulation is the most effective when administered for a rheumatoid arthritis patient prior to therapy. Thus, the most effective treatment plan can be established for each patient by selecting the optimal biological formulation for each patient.
- In this manner, a rheumatoid arthritis patient for whom administration of a biological formulation is effective can be identified by utilizing the present invention. Thus, for patients, the present invention is beneficial in terms of medical cost containment, sense of security from the prediction of a therapeutic effect and the like. For physicians, the present invention enables the establishment of a suitable treatment plan based on an accurate prediction of effectiveness of a biological formulation.
- Furthermore, the present invention does not require complex and time-consuming genetic analysis which lacks versatility. In addition, the present invention uses the concentration of a specific cytokine, chemokine, and/or soluble receptor in a serum as an indicator. Thus, the present invention can estimate in advance the effectiveness of a biological formulation targeting an inflammatory cytokine for each patient in a simple and cost-effective manner by using an existing method of measurement.
-
- [
Figure 1] Figure 1 is a diagram showing trial profiles of tocilizumab therapy patients and etanercept therapy patients. - [
Figure 2] Figures 2-1 to 2-4 are diagrams showing clinical baseline individual group statistics for healthy individuals and rheumatoid arthritis patients with respect to serum concentrations of cytokines/chemokines/soluble receptors. - [
Figure 3] Figure 3 is a diagram showing the relationship between DAS-28 values prior to therapy and DAS-28 values after 16 weeks of therapy in tocilizumab therapy patients and etanercept therapy patients. - [
Figure 4] Figure 4 is a diagram showing the relationship between DAS-28 values prior to therapy (PreDAS-28 score) and values obtained from subtracting a DAS-28 value after 16 weeks from a DAS-28 value prior to therapy (PreDAS-28score - 16W DAS-28 score) in naive patients who received tocilizumab therapy. - [
Figure 5] Figure 5 is a diagram showing results of comparing predicted DAS-28 values after 16 weeks of therapy calculated from regression equation (4) prior to therapy and actual DAS-28 values after 16 weeks of therapy subjecting naive patients who received tocilizumab therapy. - [
Figure 6] Figure 6 is a diagram showing results of comparing predicted DAS-28 values after 16 weeks of therapy calculated from regression equation (5) prior to therapy and actual DAS-28 values after 16 weeks of therapy subjecting switch patients who received tocilizumab therapy. - [
Figure 7] Figure 7 is a diagram showing results of comparing predicted DAS-28 values after 16 weeks of therapy calculated from regression equation (7) prior to therapy and actual DAS-28 values after 16 weeks of therapy subjecting naive patients who received etanercept therapy. - [
Figure 8] Figure 8 is a diagram showing the relationship between actual values of DAS-28 after 16 weeks of etanercept therapy and predicted DAS-28 values after 16 weeks of therapy estimated by assuming a patient has received tocilizumab therapy in naive patients who received etanercept therapy. - [
Figure 9] Figure 9 is a diagram showing results of analyzing the relationship between serum sgp130 concentrations and DAS-28 values prior to therapy for patients in remission and non-remission. - The present invention is a method of determining a therapeutic efficacy of a biological formulation targeting an inflammatory cytokine on a rheumatoid arthritis patient, characterized in comprising the step of measuring a concentration of one or more types selected from the group consisting of sgp130, IP-10, sTNFRI, sTNFRII, GM-CSF, IL-1β, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, Eotaxin, VEGF, MCP-1, TNF-α, IFN-γ, FGFbasic, PDGF-bb, sIL-6R, and MIP-1α in a serum collected from the rheumatoid arthritis patient prior to the administration of the biological formulation. Hereinafter, the determining method of the present invention is discussed in detail.
- The determining method of the present invention is a method of predicting and determining a therapeutic effect of a biological formulation targeting an inflammatory cytokine on a rheumatoid arthritis patient.
- A biological formulation targeting an inflammatory cytokine is not particularly limited as long as it is a biological formulation used in rheumatoid arthritis therapy. A therapeutic effect can be predicted and determined in accordance with the type of biological formulation to be used in the determining method of the present invention. Examples of a biological formulation targeting an inflammatory cytokine include anti-IL-6 agents, anti-TNF-α agents and the like. Specific examples of anti-IL-6 agent include humanized anti-IL-6 receptor antibodies, anti-TNF-α antibodies, human soluble TNF/LTα receptors consisting of an Fc region of human IgG1 and a subunit dimer of an extracellular domain of a human tumor necrosis factor receptor II, and the like. More specific examples of the humanized anti-IL-6 receptor antibodies include tocilizumab. Further, examples of the human soluble TNF/LTα receptors more specifically include etanercept. Further, examples of the anti-TNF-α antibodies more specifically include adalimumab and infliximab.
- Examples of optimal biological formulations thereamong which are applied in the determining method of the present invention include humanized anti-IL-6 receptor antibodies and humanized soluble TNF/LTα receptors, and still preferably tocilizumab and etanercept.
- The determining method of the present invention determines whether administration of a biological formulation is effective in a rheumatoid arthritis patient prior to administration of the biological formulation.
- Further, target rheumatoid arthritis patients in the determining method of the present invention are not particularly limited, as long as it is prior to administration of the biological formulation. In addition, whether DMARDs such as methotrexate are administered, past dosing history of anti-cytokine therapy (administration of infliximab etanercept, adalimumab, tocilizumab or the like) are not relevant. A therapeutic effect due to a biological formulation can be predicted and determined by selecting a desired determination marker in accordance with the past dosing history of the biological formulation in the determining method of the present invention.
- The determining method of the present invention uses one or two or more types of determination markers selected from the group consisting of sgp130 (soluble gp130), IP-10 (interferon-inducible protein 10), sTNFRI (soluble receptors for tumor necrosis factor type I), sTNFRII (soluble receptors for tumor necrosis factor type II), GM-CSF (granulocyte macrophage colony-stimulating factor), IL-1β (interleukin-1β), IL-2 (interleukin-2), IL-5 (interleukin-5), IL-6 (interleukin-6), IL-7 (interleukin-7), IL-8 (interleukin-8), IL-9 (interleukin-9), IL-10 (interleukin-10), IL-12 (interleukin-12), IL-13 (interleukin-13), IL-15 (interleukin-15), Eotaxin, VEGF (vascular endothelial growth factor), MCP-1 (monocyte chemotactic protein-1), TNF-α (tumor necrosis factor-α), IFN-γ (interferon-γ), FGFbasic (basic fibroblast growth factor), PDGF-bb (platelet-derived growth factor bb), sIL-6R (soluble receptors for interleukin-6), and MIP-1α (macrophage inflammatory protein-1α) in the serum of the rheumatoid arthritis patient.
- One type of the aforementioned specific cytokine, chemokine, and soluble receptor may be used alone as a determination marker in the determining method of the present invention. However, it is preferable to use two or more types from thereamong in combination as a determination marker, from the viewpoint of predicting and determining a therapeutic effect due to a biological formulation at a higher precision.
- The determination marker is appropriately selected and used, depending on the therapeutic effect to be predicted and determined, type of biological formulation to be administered, past dosing history of biological formulation or the like. Specific optimal examples of determination marker are shown below for each therapeutic effect to be predicted and determined.
- For a naive patient administered with tocilizumab (hereinafter, also referred to as an "tocilizumab therapy naive patient"), it is preferable to use at least one type selected from the group consisting of IL-7, IL-8, IL-12, IL-13, IP-10, VEGF, IL-1β, TNF-α, and sIL-6R as a determination marker. It is more preferable to use IL-1β, IL-7, TNF-α, and sIL-6R in combination as a determination marker.
- For a switch patient administered with tocilizumab (hereinafter, also referred to as a "tocilizumab therapy switch patient"), it is preferable to use at least one type selected from the group consisting of IL-1β, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, FGFbasic, GM-CSF, IFN-γ, TNF-α, and VEGF as a determination marker.
- For a naive patient administered with etanercept (hereinafter, also referred to as an "etanercept therapy naive patient"), it is preferable to use at least one type selected from the group consisting of IL-6, IP-10, IL-2, IL-13, IL-15, sIL-6R, and sTNFRI as a determination marker. It is more preferable to use a combination of IL-2, IL-15, sIL-6R, and sTNFRI as a determination marker.
- For a tocilizumab therapy naive patient, it is preferable to use at least one type selected from the group consisting of sgp130, IL-8, Eotaxin, IP-10, sTNFRI, sTNFRII, IL-6, and VEGF as a determination marker. It is more preferable to use a combination of sgp130, IL-8, Eotaxin, IP-10, sTNFRI, sTNFRII, and IL-6, or a combination of sgp130, IL-8, Eotaxin, IP-10, sTNFRI, sTNFRII, IL-6, and VEGF as a determination marker.
- For a tocilizumab therapy switch patient, it is preferable to use at least one type selected from the group consisting of sgp130, IL-1β, IL-2, IL-5, IL-15, GM-CSF, IFN-γ, TNF-α, and IP-10 as a determination marker. It is more preferable to use a combination of sgp130, IP-10, and GM-CSF as a determination marker.
- For an etanercept therapy naive patient, it is preferable to use at least one type selected from the group consisting of IL-9, IL-6, IL-13, TNF-α, and VEGF as a determination marker. It is more preferable to use a combination of IL-9, TNF-α, and VEGF, or a combination of IL-6 and IL-13 as a determination marker.
- For patients administered with tocilizumab (including both tocilizumab therapy naive patients and tocilizumab therapy switch patients), it is preferable to use at least one type selected from the group consisting of sgp130, IP-10, sTNFRII, IL-6, IL-7, MCP-1 and IL-1β as a determination marker. It is more preferable to use at least sgp130, and even more preferable to use a combination of (i) sgp130, (ii) IP-10, (iii) sTNFRII, and (iv) IL-6, IL-7, MCP-1 or IL-1β. More specifically, for tocilizumab therapy naive patients, a combination of (i) sgp130, (ii) IP-10, (iii) sTNFRII, and (iv) IL-6, IL-7, MCP-1 or IL-1β is especially preferable as a determination marker. Further, for tocilizumab therapy switch patients, a combination of (i) sgp130, (ii) IP-10, (iii) sTNFRII, and (iv) IL-6 or IL-1β is especially preferable as a determination marker.
- For an etanercept therapy naive patient, it is preferable to use at least one type selected from the group consisting of IL-9, TNF-α, VEGF, PDGF-bb, and MIP-1α as a determination marker. It is especially preferable to use a combination of IL-9 and TNF-α, a combination of VEGF and PDGF-bb, or a combination of MIP-1α and PDGF-bb as a determination marker.
- It is known that serum concentration of each of the cytokines, chemokines, and soluble receptors used as a determination marker can be measured by a measurement system utilizing an antigen-antibody reaction such as ELISA. Such measuring kits are commercially available. Thus , the cytokines , chemokines, and soluble receptors can be measured with a known measuring kit by a known method in the determining method of the present invention.
- A therapeutic effect due to a biological formulation can be predicted and determined based on a measured value of the determination marker. For example, the prediction and determination include a method in which the determination marker is measured in advance for patients in full remission and patients who are not in remission from therapy with a biological formulation; a regression equation of a measured value of the determination marker (explanatory variable) and a therapeutic effect of biological formulation (objective variable) are found by regression analysis; and a measured value of a determination marker of a rheumatoid arthritis patient targeted for determination is applied to said regression equation. When finding a regression equation, it is preferable to use a log value of serum concentration (pg/ml) for the determination markers other than sgp130. For sgp130, a value of serum concentration (µg/ml) is preferably used. Further, it is preferable that a regression equation is derived by multiple regression analysis. The objective variable in the above-described regression equation may be appropriately determined based on the therapeutic effect to be predicted and determined.
- For example, when predicting and determining the level of improvement in a symptom after therapy for a biological formulation, the objective variable may be set to "a value obtained by subtracting a value of a disease activity indicator after a predetermined period of therapy from a value of a disease activity indicator prior to therapy" for analysis by multiple linear regression analysis. For example, when predicting and determining a value of a disease activity indicator after therapy for a biological formulation, the objective variable may be set to "a value of disease activity indicator after a predetermined period of therapy" for analysis by multiple linear regression analysis. In this regard, specific examples of a value of a disease activity indicator include a DAS (Disease activity score)-28 value, CDAI (Clinical Disease Activity Index) value, SDAI (Simple Disease Activity Index) value and the like. A DAS-28 value, CDAI value and SDAI value are correlated with one another and reflect a symptom of rheumatoid arthritis. Thus, any of such disease activity indicator values may be used in the determining method of the present invention. Further, a disease activity indicator used in the determining method of the present invention is not limited to those exemplified above. Indicators that may be newly advocated in the future can be used.
- Further, when predicting or determining the possibility of remission due to therapy with a biological formulation (result of whether there is remission or no remission), multiple logistic regression analysis may be used for analysis.
- For regression analysis utilizing a measured value of the determination marker as an explanatory variable, a value of a disease activity indicator prior to therapy (DAS-28 value, CDAI value, SDAI value or the like) or a result of evaluation by a Boolean method may be utilized as an explanatory variable.
- Hereinafter, therapeutic effects to be predicted and determined are separated into a level of improvement in a symptom after therapy, DAS-28 value after therapy, and possibility of remission to disclose specific methods for the determining method of the present invention. However, the determining method of the present invention should not be interpreted to be limited to the following specific methods.
- A level of improvement in a symptom after therapy due to a biological formulation can be predicted and determined by multiple linear regression analysis while setting an objective variable as "a value obtained by subtracting a value of a disease activity indicator after a predetermined period of therapy from a value of a disease activity indicator prior to therapy" and an explanatory variable as "a measured value of the determination marker".
- In Examples described below, the following equations (1) and (2) have been discovered as regression equations for predicting and determining a level of improvement in a symptom after 16 weeks of therapy due to a biological formulation (level of improvement in DAS-28 value; DAS-28 value prior to therapy - DAS-28 value after 16 weeks of therapy), separated by the past dosing history of a rheumatoid arthritis patient and type of biological formulation. A level of improvement in a symptom after 16 weeks of therapy can be predicted and determined by finding an objective variable from applying values to one of the following regression equations (1) and (2) depending on the past dosing history of a rheumatoid arthritis patient subjected to determination and type of biological formulation. A level of improvement in a symptom due to a biological formulation is predicted and determined to be large for the patient for larger values of the objective variable calculated by the following regression equation.
-
- A: log value of serum IL-1β concentration (pg/ml)
- B: log value of serum IL-7 concentration (pg/ml)
- C: log value of serum TNF-α concentration (pg/ml)
- D: log value of serum sIL-6R concentration (pg/ml)
-
- E: log value of serum IL-2 concentration (pg/ml)
- F: log value of serum IL-15 concentration (pg/ml)
- D: log value of serum sIL-6R concentration (pg/ml)
- G: log value of serum sTNFRII concentration (pg/ml)
- The regression equations (1) and (2) demonstrate an example of a regression equation used to predict and determine a level of improvement in DAS-28 value after 16 weeks of therapy due to a biological formulation. However, a level of improvement in a CDAI value or an SDAI value after 16 weeks of therapy due to a biological formulation (level of improvement in CDAI value or SDAI value; CDAI value or SDAI value prior to therapy - CDAI value or SDAI value after 16 weeks of therapy) can naturally be predicted and determined by multiple linear regression analysis by the same method using a CDAI value or SDAI value. Further, since a therapeutic effect stabilizes and appears after 16 weeks of therapy by a biological formulation, regression equations for predicting and determining a level of improvement in a symptom after 16 weeks of therapy are shown in the above-described regression equations (1) and (2). Naturally, a level of improvement in a symptom before or after 16 weeks of therapy due to the biological formulations can be predicted and determined by multiple linear regression analysis using the same method.
- In Examples described below, the following equations (3)-(7) have been discovered as regression equations for predicting and determining a DAS-28 value of a symptom after 16 weeks of therapy due to a biological formulation, separated by the past dosing history of a rheumatism patient and type of biological formulation. A DAS-28 value after 16 weeks of therapy can be predicted and determined by finding an objective variable from applying values to one of the following regression equations (3)-(7), depending on the past dosing history of a rheumatoid arthritis patient subjected to determination and type of biological formulation. When the objective variable calculated by the following regression equation is 2.3 or less, the patient is predicted and determined to reach remission due to a biological formulation.
-
- H: serum sgp130 concentration (µg/ml)
- I: log value of serum IL-8 concentration (pg/ml)
- J: log value of serum Eotaxin concentration (pg/ml)
- K: log value of serum IP-10 concentration (pg/ml)
- L: log value of serum sTNFRII concentration (pg/ml)
- G: log value of serum sTNFRII concentration (pg/ml)
- M: log value of serum IL-6 concentration (pg/ml)
- N: log value of serum VEGF concentration (pg/ml)
-
- H: serum sgp130 concentration (µg/ml)
- I: log value of serum IL-8 concentration (pg/ml)
- J: log value of serum Eotaxin concentration (pg/ml)
- K: log value of serum IP-10 concentration (pg/ml)
- L: log value of serum sTNFRII concentration (pg/ml)
- G: log value of serum sTNFRII concentration (pg/ml)
- M: log value of serum IL-6 concentration (pg/ml)
-
- H: serum sgp130 concentration (µg/ml)
- K: log value of serum IP-10 concentration (pg/ml)
- O: log value of serum GM-CSF concentration (pg/ml)
-
- a: DAS-28 value prior to etanercept administration
- M: log value of serum IL-6 concentration (pg/ml)
- P: log value of serum IL-13 concentration (pg/ml)
-
- S: log value of serum IL-9 concentration (pg/ml)
- C: log value of serum TNF-α concentration (pg/ml)
- N: log value of serum VEGF concentration (pg/ml)
- Since regression equation (7) does not use a DAS-28 value prior to etanercept administration as an explanatory variable, a DAS-28 value after 16 weeks of therapy can be predicted while eliminating a subjective opinion of a physician. Thus, regression equation (7) is considered preferable over regression equation (6).
- The regression equations (3)-(7) show examples of a regression equation used to predict and determine a DAS-28 value after 16 weeks of therapy due to a biological formulation. However, a CDAI value or SDAI value itself after 16 weeks of therapy due to a biological formulation can naturally be predicted and determined by multiple linear regression analysis by the same method using a CDAI value or SDAI value. Further, as discussed above, since a therapeutic effect stabilizes and appears after 16 weeks of therapy due to a biological formulation, regression equations for predicting and determining a value of a disease activity indicator after 16 weeks of therapy are shown in the above-described regression equations (3)-(7). However, a value of disease activity indicator prior to or after 16 weeks of therapy due to the biological formulations can naturally be predicted and determined by multiple linear regression analysis using the same method.
- In Examples described below, the following equations (8)-(16) have been discovered as regression equations for predicting and determining the possibility of remission (either remission or not in remission) after 16 weeks of therapy due to a biological formulation, separated by the past dosing history of a rheumatoid arthritis patient and type of biological formulation. It is possible to predict and determine whether remission is reached after 16 weeks of therapy by finding the probability (p) of remission after 16 weeks of therapy from applying values to one of the following regression equations (8)-(16) depending on the past dosing history of a rheumatoid arthritis patient subjected to determination and type of biological formulation. The probability of remission estimated from the following regression equations (8) - (16) refers to the probability of a DAS-28 value being 2.3 or less. A p value computed from regression equations (8)-(16) closer to 1 indicates a higher possibility of remission after 16 weeks of therapy. For example, the p value of 0.5 or higher can predict and determine remission and less than 0.5 can predict and determine no remission for convenience's sake. In this regard, a DAS-28 value of 2.3 is used as the boundary between remission and non-remission to enhance the precision of prediction and determination of remission because a CRP value tends to decrease and DAS-28 value may decreases regardless of inflammation by inhibiting IL-6. The value is set at a lower value of DAS-28 value (2.6), which is generally considered the boundary between remission and non-remission.
-
- p: probability of remission after 16 weeks of therapy H: serum sgp130 concentration (µg/ml)
- K: log value of serum IP-10 concentration (pg/ml)
- G: log value of serum sTNFRII concentration (pg/ml)
- M: log value of serum IL-6 concentration (pg/ml)
-
- p: probability of remission after 16 weeks of therapy
- H: serum sgp130 concentration (µg/ml)
- K: log value of serum IP-10 concentration (pg/ml)
- G: log value of serum sTNFRII concentration (pg/ml)
- M: log value of serum IL-7 concentration (pg/ml)
-
- p: probability of remission after 16 weeks of therapy
- H: serum sgp130 concentration (µg/ml)
- K: log value of serum IP-10 concentration (pg/ml)
- G: log value of serum sTNFRII concentration (pg/ml)
- P: log value of serum MCP-1 concentration (pg/ml)
-
- p: probability of remission after 16 weeks of therapy
- H: serum sgp130 concentration (µg/ml)
- K: log value of serum IP-10 concentration (pg/ml)
- G: log value of serum sTNFRII concentration (pg/ml)
- A: log value of serum IL-1β concentration (pg/ml)
-
- p: probability of remission after 16 weeks of therapy
- H: serum sgp130 concentration (µg/ml)
- K: log value of serum IP-10 concentration (pg/ml)
- G: log value of serum sTNFRII concentration (pg/ml)
- M: log value of serum IL-6 concentration (pg/ml)
-
- p: probability of remission after 16 weeks of therapy
- H: serum sgp130 concentration (µg/ml)
- K: log value of serum IP-10 concentration (pg/ml)
- G: log value of serum sTNFRII concentration (pg/ml)
- A: log value of serum IL-1β concentration (pg/ml)
-
- p: probability of remission after 16 weeks of therapy
- a: DAS-28 value prior to etanercept administration
- E: log value of serum VEGF concentration (pg/ml)
- Q: log value of serum PDGF-bb concentration (pg/ml)
-
- p: probability of remission after 16 weeks of therapy
- a: DAS-28 value prior to etanercept administration
- R: log value of serum MIP-1α concentration (pg/ml)
- Q: log value of serum PDGF-bb concentration (pg/ml)
-
- p: probability of remission after 16 weeks of therapy
- S: log value of serum IL-9 concentration (pg/ml)
- C: log value of serum TNF-α concentration (pg/ml)
- Since the regression equation (16) does not use a DAS-28 value prior to etanercept administration as an explanatory variable, the possibility of remission can be predicted while eliminating a subjective opinion of a physician. Thus, regression equation (16) is considered preferable over regression equations (14) and (15).
- The regression equations (6)-(16) show examples of a regression equation for predicting and determining the possibility of remission after 16 weeks of therapy, with a DAS-28 value after 16 weeks of therapy of 2.3 or lower considered remission and the value over 2.3 as non-remission. However, the possibility of remission after 16 weeks of therapy due to a biological formulation can naturally be predicted and determined by multiple logistic regression analysis with the same method using a CDAI value or SDAI value. Further, as discussed above, since a therapeutic effect stabilizes and appears after 16 weeks of therapy by a biological formulation, regression equations for predicting and determining the possibility of remission after 16 weeks of therapy are shown in the above-described regression equations (6) - (16). However, the possibility of remission prior to or after 16 weeks of therapy due to a biological formulation can be predicted and determined by multiple logistic regression analysis using the same method.
- The determining method of the present invention can predict the therapeutic effectiveness of a biological formulation prior to the administration thereof. Thus, the method can be utilized in selecting the optimal biological formulation that should be administered prior to starting therapy.
- For example, for a level of improvement in a symptom after therapy of a naive patient, cases in which tocilizumab is administered and cases in which etanercept is administered are each predicted by the aforementioned method and a biological formulation with a higher level of improvement is selected, so that an optimal biological formulation can be administered to the patient. Specifically, a level of improvement in a symptom after therapy with tocilizumab therapy, which is predicted by using regression equation (1) is compared to a level of improvement in a symptom after therapy with etanercept therapy, which is predicted by using regression equation (2), so that the biological formulation with a higher level of improvement can be selected as the optimal biological formulation.
- For example, for a DAS-28 value after 16 weeks of therapy of a naive patient, cases in which tocilizumab is administered and cases in which etanercept is administered are each predicted by the aforementioned method and a biological formulation with a lower DAS-28 value after 16 weeks of therapy is selected so that an optimal biological formulation can be administered to the patient. Specifically, a DAS-28 value after 16 weeks of therapy with tocilizumab therapy, which is predicted by using one of regression equations (3)-(5) is compared to a DAS-28 value after 16 weeks of therapy with etanercept therapy, which is predicted by using regression equation (6) or (7), so that the biological formulation with a smaller DAS-28 value can be selected as the optimal biological formulation.
- For example, for the possibility of remission of a naive patient, cases in which tocilizumab is administered and cases in which etanercept is administered are each predicted by the aforementioned method to select a biological formulation with a higher possibility of remission, so that the optimal biological formulation can be administered to the patient. Specifically, the possibility of remission with tocilizumab therapy, which is predicted by using one of regression equations (8) - (11), is compared to the possibility of remission , which is predicted by using one of regression equations (14)-(16), so that the biological formulation with a higher possibility of remission can be selected as the optimal biological formulation.
- The present invention further provides a diagnostic agent for carrying out the above-described detection method. Specifically, the diagnostic agent of the present invention is a diagnostic agent for determining the effectiveness of therapy due to a biological formulation targeting an inflammatory cytokine for a rheumatoid arthritis patient, characterized by comprising a reagent capable of detecting at least one type of determination marker selected from the group consisting of sgp130, IP-10, sTNFRI, sTNFRII, GM-CSF, IL-1β, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, Eotaxin, VEGF, MCP-1, TNF-α, IFN-γ, FGFbasic, PDGF-bb, sIL-6R, and MIP-1α.
- The determination marker can be measured by a measurement system utilizing an antigen-antibody reaction such as ELISA. Specific examples of reagents capable of detecting the determination marker include antibodies that can specifically bind to the determination marker and fragments thereof. Further, antibodies that can specifically bind to the determination marker may be bound on a suitable support to be provided as an antibody array.
- Furthermore, the diagnostic agent of the present invention may comprise a reagent (secondary antibody, color producing substance or the like) required for detecting the determination marker by an antigen-antibody reaction.
- Hereinafter, the present invention is disclosed in detail while using Examples. However, the present invention is not limited thereby.
- Hereinafter, a rheumatism patient who has not received anti-cytokine therapy (administration of infliximab, etanercept, adalimumab, tocilizumab or the like) in the past is referred to as a naive patient, and a rheumatism patient who has received anti-cytokine therapy in the past is referred to as a switch patient.
- 155 rheumatoid arthritis patients, to whom methotrexate therapy was ineffective, were registered at the Higashihiroshima Memorial Hospital from March 2008 to June 2013. Among the 155 patients, 98 patients received therapy with tocilizumab and the remaining 57 patients received therapy with etanercept. Among the 98 patients who received therapy with tocilizumab, 58 patients were naive patients who had not previously received anti-cytokine therapy and 40 patients were switch patients who had previously received anti-cytokine therapy 1-3 times. Among 57 patients who received etanercept therapy, 49 patients were naive patients who had not previously received anti-cytokine therapy, and the remaining 8 patients were switch patients who had previously received anti-cytokine therapy. Informed consent was obtained prior to receiving a blood sample supply from all patients. Further, the tests were conducted with permission prior to the study from the ethics committee of the Higashihiroshima Memorial Hospital.
- Table 1 shows the clinical baseline individual group statistics for group of individuals and clinical diagnosis. Further,
Figure 1 shows a trial profile of patients receiving therapy with tocilizumab and patients receiving therapy with etanercept.Figures 2-1 to 2-4 show serum concentration of cytokine/chemokine/soluble receptor prior to therapy. 9 naïve patients (8 patients who suffered from side effects or other diseases and 1 patient for whom data could not be obtained for the entire 16 weeks) among patients treated with tocilizumab were eliminated. Further, 1 switch patient suffering from a side effect (patient for whom data could not be obtained for the entire 16 weeks) among patients treated with tocilizumab was eliminated. There was hardly any difference in DAS-28 value, CRP, swollen joint count, tender joint count, Stage, and Class among the groups (Table 1). Further, the duration of disease was shorter for patients treated with etanercept in comparison to patients treated with tocilizumab (Table 1). - In order to create a baseline concentration of cytokines, serum was collected from healthy individuals (56 individual; 20 males and 36 females) without a history of suffering from hepatitis C or cancer. The healthy individuals underwent medical examination by the Louis Pasteur Center for Medical Research or the Higashihiroshima Memorial Hospital and informed consent was received in writing from the healthy individuals. The baseline concentration was used to find a distribution pattern of cytokines/chemokines/soluble receptors.
- Prior to therapy, concentrations of cytokines, chemokines, and soluble receptors in the serum of rheumatoid arthritis patients were measured.
-
Figure 1 shows clinical results for naive patients and switch patients administered with 8 mg/kg tocilizumab or 50 mg/kg etanercept once every 4 weeks. After 16 weeks of therapy (after 4 administrations), a therapeutic effect was determined based on DAS-28-CRP values and whether the patient is in remission or non-remission. Results for non-remission were further classified into low, medium and high based on DAS-28-CRP values of the patients. DAS-28-ESR values are extensively used to determine the symptom of rheumatoid arthritis patients. However, it is reported that DAS-28-CRP values are almost interchangeable with DAS-28-ESR values and the same results are derived therefrom (Ann Rheum Dis. 2007, March 407-409 Comparison of Disease Activity Score (DAS)28-erythrocyte Sedimentation rate and DAS-C-reactive protein threshold votes. Inoue E, Yamanaka H, et al.) - In the present tests, DAS-28-CRP values were used to determine the symptoms of rheumatoid arthritis patients. Remission was classified as DAS-28-CRP value < 2.3 and non-remission was classified as DAS-28-CRP value ≥ 2.3. Furthermore, DAS-28-CRP classification system developed by Inoue et al was used to classify non-remission patients as low (DAS-28-CRP value = 2.3-2.6), medium (DAS-28-CRP value = 2.7-4.1) and high (DAS-28-CRP value > 4.1) depending of the severity of the symptoms. To obtain consistent determination of symptoms, the same physician at the Higashihiroshima Memorial Hospital determined the final symptoms of all patients. Further,
Figure 3 shows detailed clinical results of each patient shown inFigure 1 , i.e., results of determining DAS-28-CRP values prior to therapy and after 16 weeks of therapy for naive patients who received tocilizumab therapy, switch patients who received tocilizumab therapy, and naive patients who received etanercept therapy. Hereinafter, DAS-28-CRP values may be denoted simply as DAS-28 values. - For all measurements of cytokines, a multiplex cytokine array system (Bio-Plex 200, Bio-Rad Laboratories) was used in accordance with the product protocol thereof. Serum for all patients and healthy individuals were collected by 10 minutes of centrifugation (1600xg). All serum samples were stored at -80° C. Bio-Plex Human Cytokine 27-Plex Panel is configured such that 27 types of cytokines (IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, basic FGF, eotaxin, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-bb, RANTES, TNF-α, and VEGF) can be analyzed. In addition thereto, sIL-6R, sgp130, sTNF-RI and sTNF-RII were also analyzed (Milliplex®MAP, Human Soluble Cytokine Receptor Panel: Millipore Co. MA). In the present test, concentrations of cytokines, chemokines, and soluble receptors of 56 healthy individuals were simultaneously measured to find the distribution patterns thereof. Bio-Plex Manager software version 5.0 was used to conduct data collection and analysis.
- The distribution of cytokine/chemokine values in healthy individuals was analyzed. The log values of the values of the concentration (pg/ml) of cytokines, chemokines, and soluble receptors, other than sgp130, were used for the analysis. The values of concentration (µg/ml) were directly used for sgp130.
- First, simple linear regression analysis and multiple linear regression analysis were performed to investigate the association between cytokine/chemokine/soluble receptor concentration or clinical test values and values obtained by subtracting DAS-28 values after 16 weeks from DAS-28 values of patients at 0 weeks. Next, DAS-28 values after 16 weeks were estimated from a value computed from regression introduced with the clinical test values. Furthermore, simple logistic regression analysis and multiple logistic regression analysis were preformed to analyze the relationship between serum cytokine concentration and remission or non-remission. The resulting parameter p value of <0.05 indicates the presence of a significant difference. All statistical analysis was conducted by using the JMP 9.0 software.
- Tables 1 and 2 show clinical baseline individual group statistics, clinical diagnosis and cytokine/chemokine/soluble receptor characteristics.
Figures 2-1 to 2-4 shows clinical baseline individual group statistics for healthy individuals and rheumatoid arthritis patients with respect to serum concentrations of cytokines/chemokines/soluble receptors prior to therapy. In Table 1, Stage and Class are results of determination with respect to functional classification criteria for rheumatoid arthritis based on Steinbrocker (1949) classification (I-IV; Steinbrocker O et al: Therapeutic criteria in rheumatoid arthritis. JAMA 140:659,1949) and Hochberg (1992) classification (I-IV; Hochberg MC et al, The American College of Rheumatology 1991 revised criteria for the Classification of global functional status in rheumatoid arthritis. Arthritis and Rheumatism, 35:498-502, 1992), respectively. The results indicate that there is no clinically significant difference among the three rheumatism patient groups and the serum concentrations of cytokines/chemokines/soluble receptors in most rheumatism patients are significantly higher in comparison to healthy individuals. - 49 naive patients received 16 weeks of tocilizumab therapy. 56% of the patients thereof (27 patients) exhibited remission and the rest of the 21 patients exhibited non-remission (
Figure 1 ). Furthermore, 39 switch patients received 16 weeks of tocilizumab therapy, of which 9 patients exhibited remission and the rest of the 30 patients exhibited non-remission. - Further, 49 naive patients received 16 weeks of etanercept therapy. 18 patients thereamong exhibited remission and the remaining 31 patients exhibited non-remission (
Figure 1 ). In the present test, the number of switch patients was extremely low. Thus, only naive patients were used in the analysis for etanercept therapy. -
Figure 4 shows the relationship between a DAS-28 value prior to therapy and a value obtained from subtracting a DAS-28 value after 16 weeks from the DAS-28 value prior to therapy (PreDAS-28score - 16W DAS-28 score) in a naive patient who has received tocilizumab therapy (PreDAS-28 score). According toFigure 4 , improvement in DAS-28 values was observed after tocilizumab therapy in most naive patients. - According to the current results, about 55% of naive patients and about 23% of switch patients are expected to exhibit remission after tocilizumab therapy. Although the final symptoms are not identical, some improvement in the symptom is observed in about 45% of naive patients and about 77% of switch patients. Further, about 36.7% of naive patients are expected to exhibit remission after etanercept therapy. In addition, some improvement in the symptom is observed after etanercept therapy in about 60% of the remaining patients.
- It has been reported by Pers Y.M. et al (Rheumatology (2013) doi: 10.1093/rheumatology/ket301 First published online: September 19, 2013) that when DAS-28 values after 12-24 weeks of tocilizumab therapy were assessed from general medical examination, 40% of patients exhibited remission, and the main prediction markers were young patients, high CRP value, and patients without a cardiovascular disorder. Further, Koike T (J. Rheumatology, November 2013) et al reported 47.6% remission with respect to DAS28-ESR after 28 weeks of tocilizumab therapy. Meanwhile for etanercept, it is reported by Markenson JA et al (J. Rheumatology, July 2011, p. 1273-81) in the RADIUS study and Curitis JR et al (Ann RheumDis. 2012. 71. 206-212) in the TEMPO study that patients achieving a low disease activity of DAS-28 value ≤ 3.2 after 52 weeks and remission were 53%, and 63% when methotrexate is added. Further, Koike T et al (J. Rheumatology, October 2013, p. 1658-1668) have demonstrated that therapy of etanercept adding with methotrexate, when assessing DAS-28 values after 24 weeks, was more effective than therapy with etanercept alone or therapy adding an anti-rheumatism agent (DMARD) other than methotrexate. Furthermore, it is reported by Cannon GW et al (Clin Exp Rheumatol. November 2013) that 35% reached remission in a 3 year observation from TEMPO and RADIUS studies. Furthermore, Cannon GW et al demonstrated that patients with low disease activity are more likely exhibit remission. However, these reports do not reveal a marker for predicting and determining a therapeutic effect due to a biological formulation.
- In this regard, serum concentrations of cytokines/chemokines were used to investigate whether it is possible to estimate the level of improvement in rheumatoid arthritis based on DAS-28 values after 16 weeks of therapy.
-
Figures 2-1 to 2-4 show comparisons of baseline individual group statistics of cytokines/chemokines/soluble receptors prior to therapy for healthy individuals and three groups (naive patients who received tocilizumab therapy, switch patients who received tocilizumab therapy, naive patients who received etanercept therapy). As can be seen fromFigures 2-1 to 2-4 , serum concentration other than those for sgp130, sIL-6R and sTNFRI in rheumatoid arthritis patients were significantly higher in comparison to healthy individuals. Further, serum concentrations of cytokines/chemokines were lower in naive patients who received etanercept therapy in comparison to naive patients who received tocilizumab therapy. Further, it was revealed from this result that naive patients who received tocilizumab therapy have a higher CRP value prior to therapy in comparison to naive patients who received etanercept therapy. - Simple linear regression analysis was performed to find the cytokine/chemokine involved in the level of improvement in DAS-28 values. The level of improvement in a DAS-28 value (DAS-28 value prior to therapy - DAS-28 value after 16 weeks of therapy) was used as an objective variable and serum concentration of cytokines/chemokines/soluble receptors were used directly, or by converting into a log value, as an independent variable. The results are shown in Table 2. As shown in Table 2, logIL-7, logIL-8, logIL-12, logIL-13, logIP-10 and logVEGF exhibiting p < 0.05 significantly matched the level of improvement in DAS-28 values in naive patients who received tocilizumab therapy. Further, for switch patients who received tocilizumab therapy, logIL-1β, logIL-5, logIL-6, logIL-7, logIL-10, logIL-12, logIL-13, logIL-15, logFGF, logGM-CSF, logIFN-γ, logTNF-α and logVEGF significantly matched the level of improvement in DAS-28 values. Meanwhile, logIL-6 and logIP-10 significantly matched the level of improvement in DAS-28 values for naive patients who receivedetanercept therapy.
-
- Multiple linear regression analysis was performed to find the correlation between the level of improvement in DAS-28 value and cytokine/chemokine/soluble receptor concentration. As a result, it was found by phased multiple regression analysis that a combination of logIL-1β, logIL-7, logTNF-α and logsIL-6R is significantly correlated with the level of improvement in DAS-28 values in naive patients who received tocilizumab therapy (Table 3).
- Meanwhile, a combination of logIL-2, logIL-15, logIL-6R, and logTNFRI was found to have significant correlation with the level of improvement in DAS-28 values in naive patients who received etanercept therapy (Table 4).
[Table 3] Multiple linear regression analysis on naïve patients who received tocilizumab therapy Level of improvement in DAS-28 Objective variable: DAS-28 improvement (=0 week DAS-28 value - 16 week DAS-28 value) Naïve patients who received tocilizumab therapy Multiple regression analysis (Objective value=0w-16wDAS28) R^2 0.376 ANOVA(Analysis of variance) p=0.0004 Cytokine/Chemokine/soluble receptor Estimate p value intercept 5.505 0.1216 logHu IL-1b -3.618 0.0002 logHu IL-7 3.255 0.0002 logHu TNF-α 1.475 0.0221 logHu-sIL-6R -1.814 0.0264 [Table 4] Naïve patients who received etanercept therapy Multiple linear regression analysis level of improvement in DAS-28 (Objective variable : DAS-28 improvement (=0 week DAS-28 value - 16 week DAS-28 value) Naïve patients who received etanercept therapy Multiple regression analysis (Objective value=0w-16wDAS28) R^2 0.343 ANOVA(Analysis of variance) p=0.0037 Cytokine/Chemokine/sol uble receptor Estimate p value intercept 7.325 0.0231 logHu IL-2 -1.567 0.0058 logHu IL-15 1.632 0.0008 logHusIL-6R -2.540 0.0130 logHu-sTNFRI 1.973 0.0115 - Simple linear regression analysis was performed to find the cytokine/chemokine/soluble receptor involved in the final assessment of a DAS-28 value after 16 weeks of therapy (16wDAS28). The DAS-28 value after 16 weeks of therapy was used as an objective variable and serum concentration of cytokines/chemokines/soluble receptors were used directly, or by converting into a log value, as an independent variable. As shown in Table 5, sgp130 exhibiting p < 0.05 significantly matched DAS-28 values after 16 weeks of therapy in naive patients who received tocilizumab therapy. Further, for switch patients who received tocilizumab therapy, logIL-1β, logIL-2, logIL-5, logIL-15, logGM-CSF, logIFN-γ, logTNF-α and sgp130 significantly matched DAS-28 values after 16 weeks of therapy. Meanwhile, logIL-9 significantly matched DAS-28 values after 16 weeks of therapy for naïve patients who received etanercept therapy.
[Table 5] Simple linear regression analysis 16-week DAS-28 Objective variable: 16-week DAS-28 Simple linear repression enlysis of cytokine / chemokine / soluble receptor based on DAS-28 16w Simple linear regression anlysis were performed to find the parameters related to 16wDAS-28 (=16wDAS28). Naïve Tocilizumab Therapy Switch Tocilizumab Therapy Naïve Etanercept Therapy Tocilizumab naïve Tocilizumab switch Etanercept naïve Cytokine/Chemokine Estimates p value Estimates p value Estimates p value logHu IL-1b pg/ml 0.094 0.681 -0.604 0.035 -0.047 0.860 logHu IL-1ra pg/ml -0.178 0.269 0.041 0.850 0.053 0.817 logHu IL-2 pg/ml -0.078 0.644 -0.482 0.012 0.179 0.341 logHu IL-4 pg/ml 0.335 0.426 -0.798 0.140 -0.190 0.661 logHu IL-5 pg/ml -0.131 0.606 -0.832 0.025 0.119 0.724 logHu IL-6 pg/ml 0.286 0.156 -0.301 0.216 0.095 0.712 logHu IL-7 pg/ml 0.026 0.933 -0.617 0.119 0.199 0.550 logHu IL-8 pg/ml 0.568 0.319 0.168 0.721 -0.175 0.756 logHu IL-9 pg/ml -0.174 0.291 -0.190 0.330 0.545 0.011 logHu IL-10 pg/ml -0.232 0.298 -0.395 0.163 0.351 0.217 logHu IL-12 pg/ml -0.202 0.438 -0.529 0.115 0.413 0.177 logHu IL-13 pg/ml -0.100 0.699 -0.533 0.096 0.467 0.236 logHu IL-15 pg/ml -0.053 0.660 -0.325 0.019 0.092 0.557 logHu IL-17 pg/ml -0.578 0.158 -0.819 0.262 -0.578 0.556 logHu Eotaxin pg/ml -0.363 0.124 -0.360 0.291 0.056 0.868 logHu FGF basic pg/ml -0.168 0.546 -0.688 0.085 0.493 0.281 logHu G-CSF pg/ml -0.321 0.380 -0.978 0.120 -0.032 0.943 logHu GM-CSF pg/ml -0.036 0.839 -0.589 0.001 0.191 0.368 logHu IFN-g pg/ml 0.038 0.879 -0.709 0.024 0.015 0.960 logHu IP-10 pg/ml -0.048 0.877 0.241 0.568 0.104 0.818 logHu MCP-1 pg/ml 0.144 0.623 -0.113 0.739 0.009 0.981 logHu MIP-1a pg/ml 0.196 0.591 -0.388 0.301 0.051 0.890 logHu PDGF-bb pg/ml 0.097 0.798 -0.165 0.720 0.794 0.301 logHu MIP-1b pg/ml 0.351 0.477 -0-284 0.573 -0.396 0.281 logHu RANTES pg/ml 0.249 0.444 -0.452 0.224 0.382 0.631 logHu TNF-a pg/ml -0.033 0.865 -0.646 0.012 0.035 0.875 logHu VEGF pg/ml 0.400 0.136 -0.042 0.902 0.573 0.132 sgp130 µ g/ml -3.785 0.046 -1.801 0.001 -3.005 0.207 logHu-sIL-6R pg/ml -0.888 0.187 -1.246 0.075 -0.754 0.336 logHu-sTNFRI pg/ml -1.028 0.039 0.033 0.955 0.094 0.902 logHu-sTNFRII pg/ml -0.179 0.766 0.078 0.728 0.690 0.115 DAS-28 0w 0.306 0.000 0.259 0.097 0.403 0.003 MMP 0.000 0.645 0.000 0.464 0.002 0.023 RF 0.001 0.378 0.000 0.818 0.000 0.504 VAS 0.003 0.642 0.004 0.560 0.006 0.334 Swollen joint count 0.069 0.000 0.066 0.183 0.081 0.022 Tender joint count 0.067 0.000 0.074 0.166 0.042 0.193 Stage 0.092 0.418 0.393 0.162 -0.197 0.232 Class 0.188 0.483 0.130 0.680 0.453 0.096 - Multiple linear regression analysis was performed to find the correlation between DAS-28 value after 16 weeks of therapy and cytokine/chemokine/soluble receptor concentration. As a result thereof, it was found by phased multiple regression analysis that a combination of sgp130, logIL-8, logEotaxin, logIP-10, logTNFRI, logTNFRII, logIL-6, and logIL-VEGF is significantly correlated with a DAS-28 value after 16 weeks of therapy in naive patients who received tocilizumab therapy as shown in Table 6. Further, it was found that there is a very significant correlation even without using logIL-VEGF (Table 7).
- Further, it was found that a combination of sgp130, logIP-10, and logGM-CSF is significantly correlated with a DAS-28 value after 16 weeks of therapy in switch patients who received tocilizumab therapy (Table 8).
- Meanwhile, a combination of DAS-28 value prior to therapy, logIL-6 and logIL-13 was also found to be significantly correlated with the level of improvement in DAS-28 value for naive patients who received etanercept therapy (Table 9). Further, a combination of logIL-9, logTNF-α, and logVEGF, even without using a DAS-28 value prior to therapy, is significantly correlated with a DAS-28 value after 16 weeks of therapy naive patients who received etanercept therapy (Table 10).
[Table 6] Tocilizumab naïve multiple linear regression analysis Objective variable 16-week DAS-28 Multiple linear regression anlysis of cytokine / chemokine / soluble receptor based on 16w DAS-28 A.Multiple regression anlysis were performed to find the parameters related to 16wDAS-28 (=16wDAS28). Naïve Tocilizumab Therapy Tocilizumab naïve Multiple regression analysis (Objective value=16wDAS28) R^2 0.646 ANOVA(Analysis of variance) P<0.0001 Cytokine/Chemokine/soluble receptor Estimate p value mtercept 6.909 0.001 sgp130# -0.534 0.002 log IL-8 3.940 <.0001 log Eotaxin -1.039 <.0001 log IP-10 -1.002 0.002 log sTNFRI -2.580 <.0001 log sTNFRII 1.407 0.030 log IL-6 0.744 0.002 log VEGF -0.850 0.039 sgp13o# : µ g/ml
others : pg/ml[Table 7] Tocilizumab naïve multiple linear regression analysis Objective variable 16-week DAS-28 Multiple linear regression anlysis of cytokine / chemokine / soluble receptor based on 16w DAS-28 A.Multiple regression analysis were performed to find the parameters related to 16wDAS-28 (=16wDAS28). Naïve Tocilizumab Therapy Tocilizumab naïve Multiply regression analysis (objective value=16wDAS28) R^2 0.605 ANOVA(Analysis of variance) p<0.0001 Cytokine/Chemokine/soluble receptor Estimate p value intercept 4.731 0.0127 sgp130# -0.543 0.003 log IL-8 2.551 <.0001 log Eotaxin -0.937 0.0004 lop IP-10 -1.116 0.0007 lop sTNFRI -2.010 0.0004 log sTNFRII 1.630 0.0152 log IL-6* 0.577 0.0096 sgp130# : µ g/ml
others : pg/ml[Table 8] Tocilizumab switch multiple linear regression analysis Objective variable 16-week DAS-28 Multiple linear regression analysis of cytokine /chemokine /soluble receptor based on 16w DAS-28 A Multiple regression anlysis were performed to find the parameters related to 16wDAS-28 (=16wDAS28). Tocilizumab switch Multiple regression analysis (Objective value=16wDAS28) R^2 0.486 ANOVA(Analysis of variance) p<0.0001 Cytokine/Chemokine/soluble receptor Estimate p value intercept 2.837 0.011 sgp130# -0.604 0.003 log IP-10 0.714 0.003 log GM-CSF -0.622 0.0003 sgp130# : µg/ml
others : pg/ml[Table 9] Multiple linear regression analysis on naïve patients who received etanercept therapy Multiple linear regression analysis of cytokine/chemokine/soluble receptor and DAS28-CRP before therapy on 16week Das-28, Objective variable: 16-week DAS-28 Naïve Etanercept Therapy Multiple regression analysis (Objective value:16wDAS28) R^2 0.321 ANOVA(Analysis sof variance) p=0.0016 Cytokine/Chemokine/soluble receptor estimate p value intercept 0.081 0.907 DAS28-CRP (Prior to therapy) 0.522 0.000 logHu IL-6 -0.969 0.015 log HuIL-13 1.409 0.015 [Table 10] Etanercept naïve multiple linear regression analysis. Objective variable 16-week DAS-28 Multiple linear regression analysis of cytokine /chemokine /soluble receptor based on 16w DAS-28 A Multiple regression analysis were performed to find the parameters related to 16wDAS-28 (=16wDAS28). Tocilizumab switch Multiple regression analysis (Objective value=16wDAS28) R^2 0.264 ANOVA(Analysis of variance) p=0.0093 Cytokine/Chemokine/soluble receptor Estimate p value intercept 0.703 0.348 log IL-9 0.646 0.007 log TNF-α -0.551 0.039 log VEGF 0.858 0.053 IL-9, TNF-α, VEGF : pg/ml - Further, regression equation (4) found based on the multiple linear regression analysis shown in Table 7 was used to find a predicted value of DAS-28 value after 16 weeks of therapy in naive patients who received tocilizumab therapy.
Figure 5 shows the results of comparing predicted values of DAS-28 values after 16 weeks of therapy calculated by regression equation (4) and actual values of DAS-28 values after 16 weeks of therapy. It was confirmed from the results that DAS-28 values after 16 weeks of therapy estimated from the results of multiple linear regression analysis shown in Table 7 are very consistent with actual values of DAS-28 values after 16 weeks of therapy. - Further, regression equation (5) found based on the multiple linear regression analysis shown in Table 8 was used to find a predicted value of DAS-28 value after 16 weeks of therapy in switch patients who received tocilizumab therapy.
Figure 6 shows the results of comparing the predicted values of DAS-28 values after 16 weeks of therapy calculated by regression equation (5) and actual values of DAS-28 values after 16 weeks of therapy. It was confirmed from the results that DAS-28 values after 16 weeks of therapy estimated from the results of multiple linear regression analysis shown in Table 8 are very consistent with actual values of DAS-28 values after 16 weeks of therapy. - Regression equation (7) found based on the multiple linear regression analysis shown in Table 10 was used to find a predicted value of DAS-28 value after 16 weeks of therapy in naive patients who received etanercept therapy.
Figure 7 shows the results of comparing predicted values of DAS-28 values after 16 weeks of therapy calculated by regression equation (7) and actual values of DAS-28 values after 16 weeks of therapy. It was confirmed from the results that DAS-28 values after 16 weeks of therapy can be estimated to a certain extent from the results of multiple linear regression analysis shown in Table 10. - Further, a predicted value of DAS-28 after 16 weeks of therapy was found by using the aforementioned regression equation (4) while assuming that naive patients who received etanercept therapy had received tocilizumab therapy without receiving etanercept therapy.
Figure 8 shows the actual values of DAS-28 after 16 weeks of etanercept therapy and predicted values of DAS-28 values after 16 weeks of therapy while assuming that tocilizumab therapy was received. From this result, naive patients who received etanercept therapy are classified into patients who are predicted to have a higher therapeutic effect when receiving tocilizumab therapy (Figure 8 a ), patients who are predicted to have barely any difference observed between etanercept therapy and tocilizumab therapy (Figure 8 b ), and patients who are predicted to have a higher therapeutic effect observed when receiving etanercept therapy (Figure 8 c ). For patients shown inFigure 8 a , tocilizumab therapy is estimated to be more effective than etanercept therapy that was actually received. Thus, it was found that a more effective therapeutic agent can be selected by estimating DAS-28 values due to tocilizumab therapy and etanercept therapy prior to therapy by the present invention. - In therapy of rheumatoid arthritis, it is desirable that even a partial improvement is observed in the symptom of a patient. However, it is most desirable to reach complete remission. In this regard, in addition to a search for various factors for estimating the final DAS-28 value, a search was conducted for cytokines/chemokines/soluble receptors for predicting whether a patient reaches complete remission.
- Data for cytokine/chemokine/soluble receptor concentrations was analyzed for complete remission and non-remission patient groups by simple logistic regression analysis. Further, Table 10 shows the results of analyzing data for cytokine/chemokine/soluble receptor concentrations for naive patients and switch patients who received tocilizumab therapy and naive patients who received etanercept therapy. It was found by simple logistic regression analysis that swollen joint count and tender joint count and DAS-28 values were significantly different between complete remission and non-remission groups. Furthermore, sgp130 was significantly different between complete remission and non-remission groups in naive and switch patients who received tocilizumab therapy (Table 11) . Meanwhile, significant difference in sgp130 was not observed between remission and non-remission groups in naive patients who received etanercept therapy (Table 11). Further,
Figure 9 shows the results of analyzing the relationship between serum sgp130 concentration and DAS-28 value prior to therapy for remission and non-remission patients. As is clear fromFigure 9 , many patients who have reached remission had a high sgp130 concentration.[Table 11] Simple logistic regression analysis Naïve patients who received tocilizumab therapy (n=48) Switch patients who received tocilizum ab therapy (n=40) Naïve patients who received etanercept therapy (n=43) Whole Model Test Parameter Estimates Whole Model Test Parameter Estimates Whole Model Test Parameter Estimates Cytokine/Chemokine Single logistic analysis, p value Estimates Single logistic analysis, p value Estimates Single logistic analysis, p value Estimates logHu IL-1b pg/ml 0.378 0.486 0.147 -1.081 0.577 -0.274 logHu IL-1ra pg/ml 0.148 -0.628 0.087 1.573 0.323 0.478 logHu IL-2 pg/ml 0.856 0.074 0.080 -1.009 0.857 0.064 logHu IL-4 pg/ml 0.534 0.638 0.420 -1.241 0.965 -0.035 logHu IL-5 pg/ml 0.814 0.143 0.189 -1.276 0.896 -0.083 logHu IL-6 pg/ml 0.184 0.663 0.270 -0.710 0.950 -0.030 logHu IL-7 pg/ml 0.585 0.401 0.233 -1.231 0.660 0.280 logHu IL-8 pg/ml 0.432 1.088 0.864 -0.207 0.751 -0.333 loghu IL-9 pq/ml 0.545 -0.242 0.289 -0.540 0.020 1.075 loghu IL-10 pg/ml 0.604 -0.281 0.196 -0.948 0.572 0.310 logHu IL-12 pg/ml 0.773 -0.181 0.113 -1.457 0.833 0.123 logHu IL-13 pg/ml 0.963 0.029 0.432 -0.669 0.671 0.322 logHu IL-15 pg/ml 0.924 0.027 0.173 -0.519 0.942 0.021 logHu IL-17 pg/ml 0.197 -1.332 0.920 0.147 0.691 -0.730 logHu Eotaxin pg/ml 0.447 -0.441 0.512 -0.590 0.639 0.299 logHu FGF basic pg/ml 0.792 -0.177 0.725 -0.371 0.402 0.773 logHu G-CSF pg/ml 0.599 -0.471 0.786 -0.450 0.901 -0.104 logHu GM-CSF pg/ml 0.910 0.104 0.099 -0.930 0.798 -0.102 logHu IFN-g pg/ml 0.536 0.369 0.190 -1.081 0.681 -0.228 loghu IP-10 pg/ml 0.647 -0.344 0.604 0.557 0.393 0.733 logHu MCP-1 pg/ml 0.402 0.593 0,696 -0.366 0.960 0.035 logHu MIP-1a pg/ml 0.428 0.698 0.305 -0.963 0.885 -0.098 logHu PDGF-bb pg/ml 0.751 0.290 0.458 0.894 0.356 1.357 logHu MIP-1b pg/ml 0.709 0.444 0.508 -0.882 0.161 -0.991 logHu RANTES pg/ml 0.748 0.252 0.866 0.166 0.823 -0.335 loghu TNF-a pg/ml 0.787 0.127 0.143 -1.020 0.694 -0.162 loghu VEGF pg/ml 0.400 0.558 0.389 -0.793 0.967 0.030 sgp130 µg/ml -18.182 0.003 -24.159 0.003 0.212 -5.882 logHu-sIL-6R pg/ml 0.118 -2.590 0.023 -5.922 0.679 0.590 logHu-sTNFRI pg/ml 0.302 -1.284 0.843 -0.306 0.566 0.591 logHu-sTNFRII pg/ml 0.719 -0.519 0.064 1.210 0.390 0.775 age 0.139 0.039 0.064 -0.073 0.444 0.019 Duretion of disease 0.228 0.041 0.221 -0059 0.414 0.033 WBC 0.173 0.000 0.434 0.000 0.057 0.000 DAS28-CRP 0.011 0.608 0.689 0.165 0.005 0.845 VAS 0.328 0.013 0.810 0.005 0.419 0.011 CRP 0.993 0.001 0.939 -0.009 0.019 0.342 RF 0.121 0.002 0.995 0.000 0.015 0.008 Swollen joint count 0.015 0.123 0.193 0.182 0.012 0.218 Tender joint count 0.014 0.123 0.363 0.137 0.046 0.147 Stage 0.237 0.328 0.352 0.651 0.615 -0.158 Class 0.459 0.481 0.806 -0.201 0.403 0.438 - A multivariable model was examined as a prediction biomarker for remission and non-remission by phased multiple forward logistic regression analysis based on serum concentration of cytokines/chemokines/soluble receptors in patients prior to administration of tocilizumab. Tables 12 and 13 show optimal combinations of prediction biomarkers for remission and non-remission found based on phased multiple forward logistic regression analysis and ROC curves. It was found from the results of analysis that sgp130, logIP-10, logsTNFRII and logIL-6 can be prediction biomarkers for determining with high precision whether remission is reached for naive patients who received tocilizumab therapy (p = 0.0004) (Table 11a). Further, it was found that logIL-7 (p = 0.0003), logIL-1β (p = 0.0005) or logMCP-1 (p = 0.0004), in combination with sgp130, logIP-10, and logsTNFRII, can be a prediction biomarker for determining with high precision whether remission is reached for naive patients who received anti-IL-6 therapy (tocilizumab therapy) (Tables 12b-12d).
- Further, it was found that a combination of sgp130, log IP-10, log sTNFRII and log IL-6 can be a prediction biomarker for determining whether remission is reached for switch patients who received tocilizumab therapy (p = 0.002) (Table 13a). Furthermore, it was also found that a combination of sgp130,log IP-10,log sTNFRII and log IL-1β can also be a predication biomarker for determining with high precision whether remission is reached (p = 0.003) (Table 13b).
- Meanwhile, p value was 0.257 for biomarker groups for predicting and determining the possibility of remission found based on the ROC curve and multiple logistic regression analysis obtained in tocilizumab therapy for naive patients who received etanercept therapy, thus demonstrating that this biomarker group cannot predict whether remission is reached (Table 14). Meanwhile, it was demonstrated that a combination of DAS-28 value prior to therapy (0wDAS-28), log VEGF, and log PDGF-bb can also predict and determine the possibility of remission to a certain extent, as shown in Table 15, by another multiple logistic regression analysis. Furthermore, it was found that a combination of log IL-9 and log TNF-α can also predict and determine the possibility of remission to a certain extent without using DAS-28 value (0wDAS-28) for naive patients who received etanercept therapy as shown in Table 16. That is, it is suggested that the pathology of rheumatoid arthritis patients is diverse, and a biomarker for predicting and determining the possibility of remission is different for patients to whom IL-6 inhibition is effective and patients for whom TNF-α inhibition is effective.
[Table 12] Tocilizumab naïve Multiple logistic regression analysis multiple logistic analysis, Objective variable:remission vs non-remission a. Whole Model Test p=0.0004 Parameter Estimates Term Estimates p value(Prob>ChiSq) Intercept -5,092 0,466 sgp130 -36,648 0,001 logHu IP-10 -4,004 0,007 logHu-sTNFRII 5,632 0,016 logHu IL-6 1,658 0,034
Curve=0.85009[Table 13] b. Whole Model Test p=0.0003 Parameter Estimates Term Estimates p value(Prob>ChiSq) Intercept -3,467 0,621 sgp130 -42,849 0,001 logHu IP-10 -4,430 0,005 logHu-sTNFRII 5,736 0,017 logHu IL-7 2,705 0,035
Curve=0.84832c. Whole Model Test p=0.0004 Parameter Estimates Term Estimates p value(Prob>ChiSq) Intercept -2,834 0,684 sgp130 -38,721 0,001 logHu IP-10 -4,664 0,007 logHu-sTNFRII 5,369 0,020 logHu MCP-1 2,502 0,040 [Table 13] d. Whole Model Test p=0.0005 Parameter Estimates Term Estimates p value(Prob>ChiSq) Intercept -1,269 0,853 sgp130 -39,538 0,001 logHu IP-10 -3,807 0,008 logHu-sTNFRII 5,086 0,026 logHu IL-1b 1,647 0,050 [Table 13] Tocilizumab switch Multiple logistic regression analysis multiple logistic analysis, Objective variable: remission vs non-remission a. Whole Model Test p=0.0020 Parameter Estimates Term Estimates p value(Prob>ChiSq) Intercept -10,935 0,190 sgp130# -29,051 0,020 logHu IP-10 4,466 0,060 logHu-sTNFRII 2,067 0,084 logHu IL-6 -2,757 0,047
sgp130#:µg/ml[Table 14] b. Whole Model Test p=0.0030 Parameter Estimates Term Estimate Prob>ChiSq Intercept -9,671 0,217 sgp130# -27,150 0,026 logHu IP-10 3,205 0,095 logHu-sTNFRII 1,914 0,090 logHu IL-1b -2,540 0,055 [Table 14] Results of multiple logistic regression analysis on naive patients who received etanercept therapy by using biomarkers for predicting and determining the possibility of remission found based on results of multiple logistic regression analysis obtained from patients who received tocilizumab therapy Parameter Whole Model Test p=0.257 Parameter Estimates Term Estimates p value(Prob>ChiSq) Intercept -6.489 0.179 sgp130 -9.591 0.150 logHu IL-6 -0.422 0.467 logHu IP-10 0.893 0.435 logHu-sTNFR II 1.789 0.235 [Table 15] Etanercept naïve Multiple logistic regression analysis multiple logistic analysis, Objective variable :remission vs non-remission Whole Model Test p=0.0034 Parameter Estimates Term Estimates p value(Prob>ChiSq) Intercept -19.058 0.025 0w DAS28-CRP 1.390 0.007 log VEGF -2.763 0.045 log PDGF-bb 4.962 0.042
Curve=0.8055Whole Model Test p=0.0071 Parameter Estimates Term Estimates p value(Prob>ChiSq) Intercept 4.491 0.031 0w DAS28-CRP 1.107 0.007 log MIP-1a -1.808 0.082 log PDGF-bb 3.930 0.069 [Table 16] Etanercept naïve Multiple logistic regression analysis multiple logistic analysis, Objective variable:remission vs non-remission Whole Model Test p=0.0115 Parameter Estimates Term Estimates p value(Prob>ChiSq) Intercept -1.004 0.337 log IL-9 1.711 0.012 log TNF-α -1.031 0.079
Claims (14)
- A method of predicting and determining a therapeutic effect of a biological formulation targeting an inflammatory cytokine on a rheumatoid arthritis patient, characterized in comprising the step of measuring a concentration of at least one type of determination marker selected from the group consisting of sgp130, IP-10, sTNFRI, sTNFRII, GM-CSF, IL-1β, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, Eotaxin, VEGF, MCP-1, TNF-α, IFN-γ, FGFbasic, PDGF-bb, sIL-6R, and MIP-1α in a serum collected from the rheumatoid arthritis patient prior to the administration of the biological formulation.
- The method of claim 1, wherein
the method is a method of predicting and determining a possibility of remission with tocilizumab, and
at least sgp130 is used as the determination marker. - The method of determining of claim 2, wherein
a patient to be administered with tocilizumab is a rheumatoid arthritis patient who has not received anti-cytokine therapy in the past, and
the determination marker is a combination of (i) sgp130, (ii) IP-10, (iii) sTNFRII, and (iv) IL-6, IL-7, MCP-1 or IL-1β. - The method of determining of claim 2, wherein
a patient to be administered with tocilizumab is a rheumatoid arthritis patient who has received anti-cytokine therapy in the past, and
the determination marker is a combination of (i) sgp130, (ii) IP-10, (iii) sTNFRII, and (iv) IL-6 or IL-1β. - The method of determining of claim 1, wherein
the method is a method of predicting and determining a possibility of remission with etanercept in a rheumatism patient who has not received anti-cytokine therapy in the past, and
the determination marker is a combination of IL-9 and TNF-α, a combination of VEGF and PDGF-bb, or a combination of MIP-1α and PDGF-bb. - The method of determining of claim 1, wherein
the method is a method of predicting and determining a disease activity indicator after therapy with tocilizumab in a rheumatism patient who has not received anti-cytokine therapy in the past, and
wherein the determination marker is a combination of sgp130, IL-8, Eotaxin, IP-10, sTNFRI, sTNFRII, and IL-6 or a combination of sgp130, IL-8, Eotaxin, IP-10, sTNFRI, sTNFRII, IL-6 andVEGF. - The method of determining of claim 1, wherein
the method is a method of predicting and determining a value of a disease activity indicator after therapy with tocilizumab in a rheumatism patient who has received anti-cytokine therapy in the past, and
the determination marker is a combination of sgp130, IP-10, and GM-CSF. - The method of determining of claim 1, wherein
the method is a method of predicting and determining a value of a disease activity indicator after therapy with etanercept in a rheumatism patient who has not received anti-cytokine therapy in the past, and
the determination marker is a combination of IL-9, TNF-α and VEGF or a combination of IL-6 and IL-13. - The method of determining of claim 1, wherein
the method is a method of predicting and determining a level of improvement in a symptom after therapy with tocilizumab in a rheumatism patient who has not received anti-cytokine therapy in the past, and
the determination marker is a combination of IL-1β, IL-7, TNF-α, and sIL-6R. - The method of determining of claim 1, wherein
the method is a method of predicting and determining a level of improvement in a symptom after therapy with etanercept in a rheumatism patient who has not received anti-cytokine therapy in the past, and
the determination marker is a combination of IL-2, IL-15, sIL-6R, and sTNFRI or a combination of IL-6 and IL-13. - A method of selecting a more effective biological formulation for therapy in a rheumatism patient who has not received anti-cytokine therapy in the past from among biological formulations consisting of tocilizumab and etanercept, comprising:predicting and determining a possibility of remission with tocilizumab in accordance with the method of determining of claim 3;predicting and determining a possibility of remission with etanercept in accordance with the method of determining of claim 5; andcomparing the possibility of remission with tocilizumab with the possibility of remission with etanercept that were predicted and determined in the aforementioned steps to select a biological formulation with a high possibility of remission.
- A method of selecting a more effective biological formulation for therapy in a rheumatism patient who has not received anti-cytokine therapy in the past from among biological formulations consisting of tocilizumab and etanercept, comprising:predicting and determining a disease activity indicator after therapy with tocilizumab in accordance with the method of determining of claim 6;predicting and determining a disease activity indicator after therapy with etanercept in accordance with the method of determining of claim 8; andcomparing the disease activity indicator after therapy with tocilizumab with the disease activity indicator after therapy with etanercept that were predicted and determined in the aforementioned steps to select a biological formulation with a low disease activity indicator after therapy.
- A method of selecting a more effective biological formulation for therapy in a rheumatism patient who has not received anti-cytokine therapy in the past from among biological formulations consisting of tocilizumab and etanercept, comprising:predicting and determining a level of improvement in a symptom after therapy with tocilizumab in accordance with the method of determining of claim 9;predicting and determining a level of improvement in a symptom after therapy with etanercept in accordance with the method of determining of claim 10; andcomparing the level of improvement in a symptom after therapy with tocilizumab with the level of improvement in a symptom after therapy with etanercept that were predicted in the aforementioned steps to select a biological formulation with a high level of improvement in a symptom after therapy.
- A diagnostic agent for predicting and determining a therapeutic effect due to a biological formulation targeting an inflammatory cytokine on a rheumatoid arthritis patient, comprising a reagent capable of detecting at least one type of marker selected from the group consisting of sgp130, IP-10, sTNFRI, sTNFRII, GM-CSF, IL-1β, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, Eotaxin, VEGF, MCP-1, TNF-α, IFN-γ, FGFbasic, PDGF-bb, sIL-6R, and MIP-1α.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013251152 | 2013-12-04 | ||
PCT/JP2014/082061 WO2015083765A1 (en) | 2013-12-04 | 2014-12-04 | Method for predicting therapeutic effect of biological preparation on rheumatoid arthritis |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3088897A1 true EP3088897A1 (en) | 2016-11-02 |
EP3088897A4 EP3088897A4 (en) | 2017-10-11 |
EP3088897B1 EP3088897B1 (en) | 2020-11-04 |
Family
ID=53273525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14867880.8A Active EP3088897B1 (en) | 2013-12-04 | 2014-12-04 | Method for predicting therapeutic effect of biological preparation on rheumatoid arthritis |
Country Status (4)
Country | Link |
---|---|
US (3) | US20160377612A1 (en) |
EP (1) | EP3088897B1 (en) |
JP (3) | JPWO2015083765A1 (en) |
WO (1) | WO2015083765A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3309553A4 (en) * | 2015-06-09 | 2019-02-13 | Osaka University | Method for predicting/evaluating therapeutic effect of biological preparation on rheumatoid arthritis |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6631072B2 (en) * | 2015-07-31 | 2020-01-15 | 富士通株式会社 | Biological simulation system and biological simulation method |
JP7033774B2 (en) * | 2017-08-25 | 2022-03-11 | 国立大学法人 東京大学 | Anti-cytokine antibody therapy |
US20210382049A1 (en) | 2018-05-15 | 2021-12-09 | Navolab Diagnosztika Kft. | Assessing responsiveness of rheumatoid arthritis patients to biological treatment |
EP3570028A1 (en) | 2018-05-15 | 2019-11-20 | MDQuest Kft. | Assessing responsiveness of rheumatoid arthritis patients to biological treatment |
EP3623816A1 (en) * | 2018-09-12 | 2020-03-18 | GLX Analytix ApS | Glx-derived molecule detection |
WO2020175633A1 (en) * | 2019-02-28 | 2020-09-03 | 吉崎 和幸 | METHOD FOR PREDICTING AND DETERMINING EFFICACY OF TREATMENT OF RHEUMATOID ARTHRITIS USING ANTI-TNF–α AGENT |
CN114594266B (en) * | 2022-03-02 | 2022-12-27 | 安徽中医药大学第一附属医院(安徽省中医院) | Application of M1 and M2 type macrophage factor as biomarker in diagnosis and treatment monitoring of rheumatoid arthritis |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA81743C2 (en) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS |
WO2007038501A2 (en) * | 2005-09-27 | 2007-04-05 | The Feinstein Institute For Medical Research | Rheumatoid arthritis markers |
JP2009225713A (en) | 2008-03-21 | 2009-10-08 | Univ Of Tsukuba | Method for judging effectiveness of infliximab |
JP2010088432A (en) | 2008-09-09 | 2010-04-22 | Kansetsu Saisei Kenkyusho:Kk | Polymorphism relating to effectiveness-side effect expression by tnf inhibitor therapy and use thereof |
JP2011182780A (en) | 2010-02-12 | 2011-09-22 | Hubit Genomix Inc | Polymorphism of efficacy and side effect expression of il-6 inhibitor treatment and use thereof |
WO2011128096A1 (en) | 2010-04-16 | 2011-10-20 | Roche Diagnostics Gmbh | Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment |
US20130274133A1 (en) | 2010-10-01 | 2013-10-17 | Rigshospitalet | Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors |
-
2014
- 2014-12-04 JP JP2015551555A patent/JPWO2015083765A1/en active Pending
- 2014-12-04 US US15/101,301 patent/US20160377612A1/en not_active Abandoned
- 2014-12-04 EP EP14867880.8A patent/EP3088897B1/en active Active
- 2014-12-04 WO PCT/JP2014/082061 patent/WO2015083765A1/en active Application Filing
-
2018
- 2018-06-11 US US16/005,536 patent/US20180372740A1/en not_active Abandoned
-
2019
- 2019-09-18 JP JP2019169663A patent/JP2019219422A/en not_active Withdrawn
-
2020
- 2020-09-17 US US17/024,476 patent/US20210255183A1/en not_active Abandoned
- 2020-12-28 JP JP2020219171A patent/JP2021063826A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3309553A4 (en) * | 2015-06-09 | 2019-02-13 | Osaka University | Method for predicting/evaluating therapeutic effect of biological preparation on rheumatoid arthritis |
Also Published As
Publication number | Publication date |
---|---|
US20180372740A1 (en) | 2018-12-27 |
US20210255183A1 (en) | 2021-08-19 |
WO2015083765A1 (en) | 2015-06-11 |
JP2021063826A (en) | 2021-04-22 |
EP3088897B1 (en) | 2020-11-04 |
JP2019219422A (en) | 2019-12-26 |
JPWO2015083765A1 (en) | 2017-03-16 |
EP3088897A4 (en) | 2017-10-11 |
US20160377612A1 (en) | 2016-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210255183A1 (en) | Method for predicting therapeutic effect of biological preparation on rheumatoid arthritis | |
Hastie et al. | Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes | |
Mitrovic et al. | New markers for adult-onset Still's disease | |
Hastie et al. | Complex association patterns for inflammatory mediators in induced sputum from subjects with asthma | |
Sucur et al. | Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells | |
Bellos et al. | The role of interleukins in preeclampsia: a comprehensive review | |
Foell et al. | Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations | |
Saha et al. | Increased sputum and bronchial biopsy IL-13 expression in severe asthma | |
Shimauchi et al. | Serum interleukin‐22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis | |
Liu et al. | Chemokine receptor expression on human eosinophils from peripheral blood and bronchoalveolar lavage fluid after segmental antigen challenge | |
Parys et al. | Serum cytokine profiling in cats with acute idiopathic cystitis | |
Cossu et al. | Earliest phase of systemic sclerosis typified by increased levels of inflammatory proteins in the serum | |
Meller et al. | Chemokine responses distinguish chemical-induced allergic from irritant skin inflammation: memory T cells make the difference | |
Echigo et al. | Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases | |
Silvagni et al. | From bed to bench and back: TNF-α, IL-23/IL-17A, and JAK-dependent inflammation in the pathogenesis of psoriatic synovitis | |
WO2015112848A1 (en) | Methods for detection of respiratory diseases | |
Aldinucci et al. | CSF/serum matrix metallopeptidase‐9 ratio discriminates neuro Behçet from multiple sclerosis | |
Shono et al. | Expression of CCR3 and CCR4 suggests a poor prognosis in mycosis fungoides and Sézary syndrome | |
US20210018514A1 (en) | Method of predicting and determining therapeutic effect on rheumatoid arthritis due to biological formulation | |
Bai et al. | Hierarchical cluster analysis of cytokine profiles reveals a cutaneous vasculitis-associated subgroup in dermatomyositis | |
Speck et al. | Plasma and bronchoalveolar lavage samples in acute lung allograft rejection: the potential role of cytokines as diagnostic markers | |
Ferretti et al. | Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients | |
Nilsson et al. | Increased B-cell activating factor, interleukin-6, and interleukin-8 in induced sputum from primary Sjögren’s syndrome patients | |
Cabrera-Rivera et al. | Increased TNF-α production in response to IL-6 in patients with systemic inflammation without infection | |
El-Gazzar et al. | IL22 in Egyptian SLE patients, could it reflect disease activity, skin or renal involvement or is it only an expensive ESR? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20160629 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/68 20060101AFI20170530BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20170911 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/68 20060101AFI20170905BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20180720 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200605 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: YOSHIZAKI, KAZUYUKI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: IWAHASHI, MITSUHIRO Inventor name: UNO, KAZUKO Inventor name: YOSHIZAKI, KAZUYUKI Inventor name: YAGI, KATSUMI |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1331490 Country of ref document: AT Kind code of ref document: T Effective date: 20201115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014072120 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20201104 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1331490 Country of ref document: AT Kind code of ref document: T Effective date: 20201104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210304 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210204 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210205 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210204 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210304 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014072120 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20201231 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20210805 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201204 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201204 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201231 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210304 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201231 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231220 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20231219 Year of fee payment: 10 Ref country code: DE Payment date: 20231214 Year of fee payment: 10 |